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Abstract 
Progesterone is essential hormone for pregnancy, which is produced by the human 
corpus luteum in early pregnancy until the placenta assumes this function. Transport of 
the cholesterol from the outer to the inner mitochondrial membrane is the rate limiting 
step for the de novo synthesis of pregnenolone (the precursor to progesterone), a process 
mediated by STARD1. STARD1 contains a C-terminal lipid binding domain which binds 
cholesterol and an N-terminal domain targeting STARD1 to the mitochondrial 
membrane. Unlike STARD1, STARD4 and STARD6 proteins lack a mitochondrial 
targeting sequence; however, they can bind cholesterol and increase steroidogenesis in 
model systems. In this study, we found both STARD4 and STARD6 mRNA expression 
in all steroidogenic compartments of human ovarian tissue. Western blots of human 
ovarian tissue demonstrated STARD4 and STARD6 immunoreactive protein at 
approximate molecular mass of 30 kDa and 43 kDa, respectively. Microscopically, 
STARD4 and STARD6 proteins are localized to steroidogenic cells of ovarian follicles 
(in granulosa and theca cells) and luteal cells. In order to determine the actual protein 
mass for ovarian STARD4, mRNA from human luteinized granulosa cells (hLGC), we 
aimed to clone all major transcripts of STARD4 from a cDNA library we generated from 
granulosa cell poly (A) RNA. Two major transcripts were isolated for STARD4. First one 
possessing all six exons with a small variation of 6 nucleotides in the untranslated exon 1 
was predicted to yield a full-length protein of 205 aa.  
 vi 
 
The second transcript possessed an exon 4 deletion, which introduced a premature stop 
codon and is predicted to yield a truncated protein with sizes of either 55 amino acids or 
107 amino acids. Both cDNAs were placed in expression vectors. The full-length 
recombinant STARD4 protein appeared on Western blot at an approximate size of 24 
kDa. Using the COS cell F2-steroidogenic assay, transfected full-length and exon 4-
deleted transcript protein functions were compared. Full-length STARD4 protein was 
able to increase the pregnenolone production significantly compared to empty vector, 
whereas truncated (exon 4 deleted) STARD4 was not. Although full-length STARD4 has 
the potential to increase steroidogenesis, it is unlikely that the truncated protein has 
similar ability. 
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Chapter I 
Introduction 
1.1 Introduction overview  
Infertility is a critical problem all over the world among couples. According to the 
American Society for Reproductive Medicine, infertility is defined by the failure to 
achieve a successful pregnancy after twelve months or more of appropriate, timed 
unprotected intercourse or therapeutic donor insemination (Definitions of Infertility and 
Recurrent Pregnancy Loss: A Committee Opinion. 2013). Around 42 million couples of 
reproductive age worldwide were affected by infertility in 1990, with the prevalence of 
infertility in 2010 being increased to 48.5 million (Mascarenhas et al. 2012). In the 
United States around 15% of couples of reproductive age suffer from infertility 
(DeAngelis et al. 2014). Infertility has different etiologies including male factors and 
female factors.  The causes of infertility in females are varied and can be either structural 
(fallopian tubes, uterus) or functional (ovary, hypothalamic-pituitary origin). Ovulation 
disorders are the most common of female infertility disorders and include polycystic 
ovarian syndrome (PCOS), primary ovarian insufficiency (POI), and premature ovarian 
failure (Infertility Reproductive Health CDC 2015). 
1.2 Anatomy of the female reproductive system 
 The female reproductive system anatomically consists of internal reproductive 
organs and external genitalia. The internal reproductive organs include two ovaries, one 
uterus with two extended tubes, which are known as Fallopian tubes, and the vagina. 
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Each ovary is located in the ovarian fossa relative to the lateral side of the pelvic wall and 
connected to the uterus by its broad ligament on both sides and the ovarian ligament. The 
ovaries are grayish-pink in color with length of 4 cm, width of 2 cm, and thickness of 8 
mm. The uterine tubes are curved on the upper border of broad ligament above the 
ovaries, then arched downward with finger-like extensions called fimbria toward the 
ovary. Histologically, the surface of the ovary is covered by squamous to columnar 
epithelial cells, and this layer of cells is called the germinal epithelium. The internal 
portion of the ovary is composed of ovarian follicles embedded into a stromal network; 
where the stroma consists of connective tissue fibers and cells. Near the ovarian surface, 
there is a thick white layer of stroma called the tunica albuginea (Henry 2000).  
Internally, the ovarian follicles, with variant size, are arranged in between outer 
cortical and inner medullary regions. Post-pubertally almost each follicle goes through 
the same developmental stages starting from primordial follicles and enlarging to form 
antral follicles (Figure 1.1). Only few follicles fully mature to the Graafian follicle stage. 
The primordial follicle is composed of one oocyte encircled by one or more layers of 
epithelial cells (follicular cells). During fetal life, primordial follicles are formed from a 
primary oocyte surrounded by a single layer of flat follicular cells. By puberty, most of 
primary follicles have undergone a degenerative process called atresia, and about only 
300,000 oocytes remain. At various times a group of follicles start to develop and 
produce a mature follicle. By mechanisms not fully understood, periodically primordial 
follicles are activated and the oocyte grows and the flat epithelium cells morphologically 
change into simple cuboidal epithelium to form a unilaminar primary follicle. The next 
stage is the multilaminar primary follicle, where the follicular cells continue to divide and  
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Figure 1.1. The ovary demonstrating different stages of follicular development. 
Schematic drawing of the developmental stages of ovarian follicles, beginning with the 
primordial follicle and ending with the pre-ovulatory or Graafian follicle. After the 
oocyte is ovulated, the residual cells of the follicle become luteal cells and will transform 
into the corpus luteum. If pregnancy is not established the corpus luteum will regress 
forming the corpus albicans. (Based on information from Junqueira’s Basic Histology, 
Mescher, 2013). 
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form multiple layers of granulosa cells around the growing oocyte. The zona pellucida 
develops between the oocyte and granulosa cell layers, which is an extracellular material 
consisting mainly of glycoproteins secreted by the oocyte (Mescher 2013).  
The antral or secondary follicle is the third stage of follicular development, where 
the follicle increases in size and creates small cavities between the granulosa cells layer 
by their follicular fluid secretions. The granulosa cells rearrange to produce one larger 
cavity called an antrum filled with follicular fluid. The follicular fluid contains estrogens, 
progesterone, and androstenedione. The follicular fluid also contains plasminogen, 
fibrinogen, heparin sulfate proteoglycan, hyaluronate, and growth factors such as insulin-
like growth factors. The stromal cells that surround the follicle proliferate and 
differentiate into two distinct layers, the theca externa and the theca interna. Thecal cells 
produce the androgen hormone androstenedione, which is transported into granulosa cells 
and converted into estrogen hormone. In humans one antral follicle is selected to be 
dominant and grows to form a mature follicle called a Graafian follicle (Mescher 2013).   
1.3 Physiology of ovulation and menstrual cycle 
In order to understand reproductive diseases, we need to understand physiology of 
female reproductive system, the ovulation process, and the cyclical changes that occur in 
the ovary. Ovulation is a physiological cyclic event which occurs in most reproductive 
age women on a monthly basis. Ovulation occurs under the influence of both follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary 
gland. Beginning at puberty and at regular intervals, there is activation of some of the 
resting follicle pool, over 2-3 months these follicles grow to reach the final maturation 
stage. During each menstrual cycle, only one follicle is chosen to continue to grow into a 
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large dominant Graafian follicle. The preovulatory (Graafian) follicle ovulates at the 
middle of each menstrual cycle, and the remnants of ovulated follicle undergoes 
luteinization to form a corpus luteum, which produces a large amount of progesterone 
within few days after ovulation.  
The maturing ovarian follicle is composed of an oocyte surrounded by granulosa 
cells and theca cells with a fluid filled antrum in the granulosa cell layers.  During the 
antral follicle stage, the thecal cells have steroidogenic activity under the influence of 
LH, where they synthesize androgens, androstenedione and testosterone. On the other 
hand, the granulosa cells of more advanced follicles have abundant of FSH receptors and 
high sensitivity to FSH which in turn upregulates the gene expression of CYP19 
(aromatase) and LH receptors; eventually, the granulosa cells of selected follicles utilize 
aromatase to convert the diffused androstenedione into estrone and testosterone into 
estradiol. The large Graafian follicle produces abundant estrogen that subsequently leads 
to the LH surge and ovulation of the oocyte, leaving the granulosa and theca cells within 
the ovary to luteinize enabling them to dramatically increase the de novo steroidogenesis 
during the luteal phase (White 2013). 
 After ovulation, the luteinized granulosa and theca, or luteal cells now have 
dramatically increased capacity to make the first steroid hormone pregnenolone from its 
primary precursor, cholesterol. Enzymes of luteal cells convert pregnenolone to 
progesterone and estrogens, however, progesterone is the main steroid hormone produced 
by luteal cells. 
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1.4 Cholesterol homeostasis  
Lipids have various forms with different functions; however, they share the same 
feature of lacking water solubility. At the level of the organism, lipids serve as energy 
storage or hormones mediators. While at the cellular level, lipids provide structural 
components of cell membranes and the membranes of cellular organelles. The major type 
of lipids are glycerolipids (glycerol and three fatty acids), sphingolipids (sphingosine, 
fatty acid and choline or mono- or oligo- saccharide), and sterols such as cholesterol 
(Alpy and Tomasetto 2014). Cholesterol is an essential structural molecule in cell 
membranes of eukaryotic cells, where it comprises around 30% of the plasma membrane 
total lipid molecules (Ikonen 2008). In addition, cholesterol is the precursor substrate for 
steroid hormones biosynthesis in the gonads (ovaries and testis), adrenal gland, and 
placenta. In addition, some central nervous system cells can make steroids (Furukawa et 
al. 1998). Cholesterol serves also as a precursor molecule for bile acid formation in the 
liver and vitamin D biosynthesis in the kidneys. The human body derives cholesterol 
either from diet or/and by de novo synthesis (Ikonen 2008); in addition, cholesterol 
homeostasis is maintained through its cellular uptake, transport/trafficking, sorting, 
biosynthesis, storage, secretion, and catabolism into bile acids (Pandak et al. 2001). 
Different lipid types, including cholesterol, are distributed variously between cell 
membrane and other compartments (Du et al. 2015); where the endoplasmic reticulum 
(ER), a major site of cholesterol synthesis and regulation, has the lowest cholesterol 
content, around 5% of lipid molecule; while, the cell membrane has the highest 
cholesterol contents (Ikonen 2008; Radhakrishnan et al. 2008). 
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Cholesterol level is tightly controlled via the feedback pathway of sterol 
regulatory element-binding protein transcription factors (SREBP). SREBP is membrane-
bound transcription factors on the endoplasmic reticulum. When the ER level of sterol is 
low, the SREBP precursor is cleaved and transferred to the Golgi complex, where it is 
transformed into its active soluble form, which migrates into the nucleus. In the nucleus, 
SREBP increases the gene expression for proteins responsible for cholesterol synthesis 
and uptake (Reinhart et al. 1987; Goldstein et al. 2006).  
  Intracellular cholesterol trafficking occurs by different mechanisms including 
vesicular transport or/and non-vesicular transport; both transport types maintain the 
heterogeneous distribution of cholesterol between the membranes of cellular organelles 
(Prinz 2002). In the non-vesicular transport, the lipid transport between adjacent 
membranes occurs via specific domains of a variety of lipid-transfer proteins (LTPs). 
This process has a huge impact on intracellular lipid trafficking and distribution; 
however, the underlying mechanism is still an area of active research (Lev 2010).  Lipid-
transfer proteins move the lipid between two organelles at membrane contact sites 
(MCSs), where the distance between the two apposed membranes is less than 30 nm. The 
MCS has specific domains of lipid-transfer proteins to exchange and shuttle  lipids such 
as cholesterol and signals such as calcium between intracellular organelles back and forth 
through the cytoplasm (Levine 2004; Helle et al. 2013).  
Since the endoplasmic reticulum is the main site of lipid synthesis, it forms MCSs 
thereby networking with associated membranes such as the plasma membrane, and 
membranes of the mitochondria, Golgi, and lysosomes. This MCS network is involved in 
lipid transfer and signaling (Levine 2004; Toulmay and Prinz 2011). Mitochondrial-
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associated ER membrane (MAM) is a MCS between the endoplasmic reticulum and 
mitochondrial membranes, where the distance is vary from 10 nm to 60 nm. Vance’s 
group was the first group to characterize the mitochondria-associated membrane fraction 
or ‘ER sub-fraction associated with mitochondria’ in rat liver (Vance 1990; Achleitner et 
al. 1999; Lebiedzinska et al. 2009). This mitochondrial fraction has a high similarity to 
rough and smooth endoplasmic reticulum and possesses typical ER housekeeping 
proteins. Indeed, the MAM fraction has several lipid-synthesizing enzymes  observed in 
the ER, including diacylglycerol acyltransferase and acyl-Coenzyme A: cholesterol acyl 
transferase (ACAT), which indicate that the MAM has a role in lipid synthesis and 
metabolism (Rusiñol et al. 1994; Vance 2003; Levine 2004).   
Oxysterol-binding protein (OSBP) is a novel example of lipid-binding protein at 
MCSs, which facilitates cholesterol movement between organelle membranes coupled 
with phosphatidylinositol 4-phosphate (Du et al. 2015). In steroidogenic cells, 
steroidogenic acute regulatory protein (StAR or STARD1) is the lipid-transfer protein 
that facilitates cholesterol transfer from the outer-mitochondrial membrane to the inner-
mitochondrial membrane (Stocco 2000). A recent study has found that StAR interacts via 
its C-terminus with a voltage-dependent anion channel 2 (VDAC2) at MAM fraction. 
They have found the absence of VDAC2 will inhibit steroidogenesis by reducing StAR 
maturation and processing into the mitochondria. The MAM fraction plays a central role 
in transferring StAR into the mitochondria (Prasad et al. 2014).  
1.5 Steroidogenesis and regulation  
Steroidogenesis is the process of synthesizing steroid hormones in a specific cell 
type, called steroidogenic cells, which is reside in specialized organs (Miller and Auchus 
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2011). Some examples of steroidogenic cells are: ovarian theca cells which produce 
androgen, ovarian granulosa cells which convert androgens to estradiol, luteal cells of 
ovarian corpus luteum and placental syncytiotrophoblasts which synthesize and secrete 
progesterone, and testicular Leydig cells which make testosterone. Further examples of 
steroid hormones are glucocorticoids, which are secreted from adrenal fasciculata cells, 
and mineralocorticoids secreted from adrenal glomerulosa cells (Stocco 2001). In 
addition, there are  neurosteroids produced in the brain, which stimulate or inhibit 
GABAergic neurons (Majewska et al. 1986). All steroid hormones are important for 
homeostasis, to manage stressful situations, regulate blood pressure, and the reproduction 
in all vertebrates including spermatogenesis in males, ovulation and the maintenance of 
the pregnancy in females. 
Steroidogenesis is regulated by anterior-pituitary hormones, ACTH 
(adrenocorticotropin hormone) stimulates the synthesis of steroid hormones from the 
adrenal gland. FSH and LH stimulate the synthesis of reproductive hormones, such as 
estrogen and progesterone from the ovary, and testosterone from testes. The regulation of 
steroidogenesis has two phases, acute and chronic regulation. The acute phase occurs in 
response to stimuli with the rapid production of steroid hormones within minutes. While 
the chronic of steroidogenesis results from the increased synthesis of new steroidogenic 
pathway enzymes (Miller 1988; Simpson et al. 1992; Stocco and Clark 1996; Stocco 
2001).  
ACTH, FSH and LH increase the level of cyclic adenosine mono-phosphate 
(cAMP) in steroidogenic cells of adrenal glands and gonads. Subsequently, cAMP 
stimulates hormone sensitive lipase (HSL), which hydrolyzes esterified cholesterol, and 
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inhibits ACAT, which is responsible for esterification of free cholesterol. By stimulating 
HSL and inhibiting of ACAT, increased intracellular free cholesterol level will be 
available for steroid hormones synthesis (Papadopoulos and Miller 2012). The 
steroidogenic cells maintain intracellular cholesterol levels either by uptake of lipoprotein 
derived cholesterol from high density lipoproteins (HDL) via scavenger receptor B1 (SR-
B1), or low density lipoprotein (LDL) via receptor-mediated endocytosis, where LDL 
attaches to LDL receptors on the cell surface and is internalized. ACTH and LH 
upregulate LDL receptors and stimulate de novo synthesis of cholesterol from acetyl Co 
A in the endoplasmic reticulum by stimulating 3-hydroxy-3-methylglutaryl co-enzyme A 
(HMGCoA) reductase, which is the rate-limiting enzyme in cholesterol synthesis ( Miller 
and Bose 2011; Papadopoulos and Miller 2012; DeAngelis et al. 2014). All these process, 
in addition to hydrolysis of stored cholesterol esters by hormone sensitive lipase enzyme,  
provide the cholesterol substrate for initial steroid hormones synthesis (Kraemer et al. 
1991). 
When the cholesterol is available for steroid synthesis, cholesterol is somehow 
transferred to StAR on the outer mitochondrial membrane. Cholesterol binds to the 
carboxyl terminus of StAR protein and is transferred to the inner mitochondrial 
membrane (IMM). Cholesterol is then cleaved by cytochrome P450 side chain cleavage 
enzyme (P450scc) complex at the IMM to form the first steroid hormone pregnenolone. 
The complex is made of P450scc, adrenodoxin, and adrenodoxin reductase. Cytochrome 
P450scc enzyme is encoded by the CYP11A1 gene and it is officially named CYP11A1 
protein. Cyclic AMP is induces P450scc expression in the cortex of the adrenal gland 
(John et al. 1986), and in the ovary and testis (Mellon and Vaisse 1989), leading to 
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upregulation of steroidogenesis. Regardless of steroidogenic tissue type, transferring and 
cleaving the cholesterol are the rate-limiting steps in de novo steroidogenesis 
(Papadopoulos and Miller 2012; Stocco 2000). Understanding the trafficking of 
cholesterol to the outer mitochondrial membrane is an area of active research by many 
laboratories because it is poorly understood and may involve other proteins related to 
StAR. 
After the first steroid hormone (pregnenolone) is made, it is converted to 
progesterone either inside the mitochondria by 3beta-hydroxysteroid dehydrogenase (3β-
HSD, mitochondrial form), or outside the mitochondria in the microsomal compartment-
ER (Figure 1.2) (Cherradi et al. 1994; Cherradi et al. 1995). The following steps in the 
steroidogenesis are regulated by several P450 enzymes such as, 17α-hydroxylase 
(P450c17/CYP17A1), which converts pregnenolone sequentially to 
dehydroepiandrsterone (DHEA) in combination with its 17,20-lyase activity. Also, it 
converts progesterone sequentially into androstenedione in androgenic tissue. CYP19A1 
(aromatase) in granulosa cells, which converts androstenedione to estradiol (White 2013).  
1.6 START domain protein family    
The steroidogenic acute regulatory protein-related lipid transfer proteins (START) 
have domains that bind and facilitate lipids transport intracellularly. The START domain 
modeled after the prototype StAR has approximately 210 amino acids in a globular 
structure of a beta sheet core and an outer surface of alpha helices. This organization of 
beta sheet and alpha helices results in a hydrophobic cavity on the internal surface for 
lipid binding, where the lipid binds to the carboxy-terminal of the alpha helix A subset of  
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Figure 1.2. Steroidogenic pathway. Cholesterol is transported from the outer 
mitochondrial membrane to the inner mitochondrial membrane in theca cells and luteal 
cells by steroidogenic acute regulatory protein (StAR). Substrates are converted by their 
specific enzymes to the next substrate in the steroidogenic pathway (LaVoie and King 
2009). Reused with permission.  
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START domain proteins bind sterols. START domain proteins are believed to control 
lipid trafficking between intracellular organelles, lipid metabolism, and signaling 
regulation (Soccio et al. 2005; Strauss et al. 2003).  In humans, fifteen proteins with 
START domains have been identified. The START domain resides almost exclusively at 
C-terminals. They are sub-defined into six subfamilies, according to their sequence 
homology. Each subfamily is specialized in transporting and/or sensing of a common 
lipid ligand; for example, StAR (STARD1) and STARD3 share the ability to transport 
cholesterol. The STARD4 subfamily proteins (STARD4, STARD5, and STARD6) 
having greatest similarity to StAR, where they bind and/or transport cholesterol. While 
STARD2, STARD7, STARD10, and STARD11 proteins sense glycerolipid and 
sphingolipid and STARD13 senses phosphatidylcholine. The lipid-binding characteristics 
of the remaining START domain proteins have been less well characterized. However, 
the same sub-family members are distinct in their expression and subcellular localization; 
hence, their biological and physiological functions are different (Alpy and Tomasetto 
2005; Alpy and Tomasetto 2014). 
StAR is the founding member of the START domain protein family. Stocco and 
his team were the first to isolate the gene and describe for the 30 kDa mitochondrial 
StAR protein in MA-10 mouse Leydig tumor cells. They purified StAR protein 
performed mass spec sequencing and cloned a cDNA of 852 base pairs in length, which 
encoded a protein with 284 amino acids (Clark et al. 1994; Stocco and Clark 1996). StAR 
is mitochondria-targeting protein, and possesses a mitochondrial-signaling sequence at 
the N-terminus. StAR transfers cholesterol from the outer mitochondrial membrane into 
the inner-mitochondria membrane by its C-terminus. Steroidogenic efficiency is 
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determined by non-vesicular transferring of cholesterol by StAR into mitochondria, 
which is considered to be the rate-limiting and most regulated step in steroidogenesis in 
the adrenal and gonads. StAR gene expression is induced by ACTH and LH hormones 
via an increase in cAMP level in their target tissues. The increase in cAMP activates 
protein kinase A (PKA) and amplifies protein synthesis, phosphorylation events, and 
lipid synthesis leading to increased  steroidogenesis (Rone et al. 2009; Soccio and 
Breslow 2004).    
StAR synthesis and activity has been shown to be regulated by both PKA and 
protein kinase C (PKC) in a cell specific manner. In Leydig cell lines, MA-10 and TC-1, 
stimulation of PKC via phorbol-12-myristate-13-acetate (PMA) increased the total 
expression of StAR, but did not increase phospho-StAR its active form (P-StAR), and 
thus was unable to increase steroid production. However, combined stimulation of PKA 
with a sub-maximal dose of dibutyryl cAMP, leads to phosphorylation of StAR and 
increased steroidogenic activity. This finding indicates the importance of cAMP/PKA 
pathway in regulating steroidogenesis (Jo et al. 2005; Stocco et al. 2005). In addition, 
cAMP activates other transcription factors that modulate genes involved in 
steroidogenesis including StAR gene. These factors include as steroidogenic factor 1(SF-
1), GATA-4, CREB, CCAAT/enhancer-binding protein (C/EBP), and SP1. Their binding 
sites are found in the 5’-flanking DNA proximal to StAR gene. Notably, the StAR 
promoter lacks a consensus cAMP response-element (CRE) often found in cAMP-
responsive genes (Stocco et al. 2001; Tremblay et al. 2002; Manna et al. 2003).  
Steroidogenesis can be activated by cAMP-independent pathways as well, such as 
growth factors, steroidogenic inducing protein, and calcium messenger signaling; 
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however, the other pathways have modest stimulation when compared to the cAMP/PKA 
pathway (Stocco et al. 2005). For example, insulin-like growth factors I and II (IGF-I and 
II) increased StAR protein expression approximately 4–5-fold (Soccio et al. 2005; Strauss 
et al. 2003). Furthermore, insulin increased StAR production by 2.5-fold in human 
luteinized granulosa cells. Production of progesterone parallels StAR levels in the same 
way in ovarian steroidogenic cells (Devoto et al. 1999).  
1.7 STARD4 regulation   
Members of the STARD4 subfamily, STARD4, STARD5, and STARD6 have a 
START domain, and each domain consists of 205 to 233 amino acid residues. There is 
approximately 30% homology between STARD4 subfamily members. Structurally, the 
STARD4 subfamily is characterized by helix-grip fold from β-sheets and α-helixes. 
Internally, a deep pocket is formed by the curved β-sheet with C-terminal of the α-helix, 
which produces an internal hydrophobic cavity, or a tunnel. Recently, x-ray structure of 
mouse STARD4 protein has been identified, and the estimation for the volume of lipid-
binding tunnel was made at 847 Å resolution. It was found that the tunnel is able to 
accommodate one molecule of cholesterol (Romanowski et al. 2002; Soccio and Breslow 
2003).  
STARD4 was identified first in the mouse liver during analysis of cDNA 
microarray data of cholesterol-regulated genes (Soccio et al. 2002). The members of 
STARD4 subfamily are predicted to be close to StAR in their ability to transport 
cholesterol. In contrast to StAR, STARD4 and STARD6 lack an N-terminal 
mitochondrial targeting sequence. Targeting sequences are used to target the protein to 
specific organelle’s membrane, which suggests cytoplasmic activity for both STARD4 
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and STARD6 although this has not been verified (Soccio et al. 2002). In the human, 
STARD4 has been identified in hepatocytes, Kupffer cells (liver macrophages in the 
parenchymal area), and THP-1 macrophages. At the subcellular level of these cells, 
STARD4 has been identified in the cytoplasm associated with ER and lipid droplets. It 
has also been co-localized with Acyl-CoA cholesterol acyltransferase-1 in ER-derived 
vesicles (Rodriguez-Agudo et al. 2011; Romanowski et al. 2002; Calderon-Dominguez et 
al. 2014).  
Evidence in hepatocytes indicates that STARD4 is a cytoplasmic protein, which 
can act as non-vesicular transporter of cholesterol between the endoplasmic reticulum 
and the plasma membrane. The STARD4 gene is sterol-regulated, where its expression is 
reduced in the liver of mice fed a high cholesterol diet. STARD4 expression is controlled 
by the transcription factor SREBP-2, where it bind to sterol regulatory elements (SREs) 
on the STARD4 proximal promoter (Soccio et al. 2005; Alpy and Tomasetto 2014). Low 
levels of endoplasmic reticulum cholesterol activate SREBP-2, which upregulates the 
genes that are responsible for increasing cholesterol synthesis, uptake, and transport such 
as HMG-CoA reductase, LDL receptor, and STARD4, respectively (Goldstein et al. 
2006). Overexpression of STARD4 increased the level of cholesterol in endoplasmic 
reticulum in mouse hepatocyte (Rodriguez-Agudo et al. 2008), where cholesterol gets 
esterified by ACAT; then esterified-cholesterol is stored in lipid droplets. Moreover, 
recombinant STARD4 has been shown to increased ACAT-1 activity, indicating that 
STARD4 participates in cholesterol esterification (Rodriguez-Agudo et al. 2011). 
Additionally, overexpression of STARD4 is increased nuclear liver X receptor (LXR) 
activity, which is involved in cholesterol metabolism. However, downregulation of 
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STARD4 by siRNA reduces the cholesterol level in endoplasmic reticulum and increases 
free cholesterol (Alpy and Tomasetto 2014; Miller 2007; Soccio et al. 2005) It was found 
that overexpression of STARD4 in STARD4-silenced cells enhanced the transport of 
sterol to the endocytic recycling compartment and to the endoplasmic reticulum (Mesmin 
et al. 2011). Conversely, only mild changes have been observed for lipid metabolism in 
STARD4 knock-out mouse. In Leydig cells, STARD4 expression was not induced by 
steroidogenic stimuli (Calderon-Dominguez et al. 2014; Riegelhaupt et al. 2010; Soccio 
et al. 2005). Nevertheless, recently the STARD4 subfamily (e.g., STARD4 and 
STARD6) has been shown experimentally to increase steroidogenesis in in vitro assays 
and in model cells, indicating STARD4 and STARD6 have the ability for cholesterol 
transport to the mitochondria (LaVoie et al. 2014; Bose et al. 2008). Additionally, non-
steroidogenic COS-1 cells transfected with STARD4, the P450scc complex, and 3β-
hydroxysteroid reductase revealed StAR-like activity of STARD4 as STARD4 was able 
to generate progesterone in this assay (Soccio et al. 2005). 
1.8 STARD4 gene  
The human STARD4 gene is located on chromosome five (5q22.1), and it has six 
exons spanning 2.2 kb. The exon length of homo sapiens STARD4 in order are 75 bp, 
113 bp, 49 bp, 126 bp, 114 bp, and 1,783 bp. Translation of STARD4 exons produces a 
wildtype protein of 200-205 amino acids. (Alpy and Tomasetto 2005; NCBI 2014 
http://www.ncbi.nlm.nih.gov/nuccore/NM_139164.1). The STARD4 gene is classified in 
NCBI’s Conserved Domain Database as a part of the SRPBCC ligand-binding domain 
superfamily. Domains have a deep hydrophobic ligand-binding pocket and bind for a 
different ligands as mentioned above (Marchler et al. 2015). Upregulation of STARD4 
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causes an increase in the level of cholesterol in the endoplasmic reticulum and cholesterol 
esterification (Soccio et al. 2005). Cholesterol trafficking between the endoplasmic 
reticulum, endocytic recycling compartment, and plasma membrane were disrupted in 
HepG2 cells when STARD4 expression was knocked down, which indicates STARD4 
plays a role in cholesterol transport by the non-vesicular pathway (Garbarino et al. 2012).  
1.9 STARD6 protein 
STARD6 is one member of STARD4 subfamily, which is characterized by 
binding cholesterol and oxysterol. Structurally, STARD6 is similar to STARD1 with 
unique C-terminus, which is sensitive to protease. STARD6 was first identified in male 
germ cells, which led to the hypothesis that the protein participates in spermatogenesis 
rather than steroidogenesis (Clark 2012; Gomes et al. 2005). However, STARD6 was 
later localized in Leydig cells and in various nervous tissues inferring a possible role in 
steroidogenesis. STARD6 was localized in the cytoplasm and nucleus of these cells 
(Chang et al. 2010). Recently, STARD6 has been detected in the luteinizing granulosa 
cells of the pig ovary, which have steroidogenic ability; however, the cAMP pathway did 
not regulate STARD6 (LaVoie et al. 2014). In vitro STARD6 efficiency in transporting 
cholesterol into adrenal mitochondria was equal to STARD1 (Bose et al. 2008). To date, 
almost nothing is known about the regulation of STARD6 at the gene or protein level.  
1.10 Diseases related to START proteins and steroid production 
Only one disease has been proven to be related to one of the START proteins, 
which is Lipoid Congenital Adrenal Hyperplasia (CAH). Lipoid CAH is a fatal disease 
caused by mutation in StAR gene associated with the complete absence of 
steroidogenesis. The most organs affected are the adrenal gland and the testis. Initially, 
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the steroidogenic tissue can keep low level of steroidogenesis by StAR-independent 
pathway; however later cells are unable to produce any steroid hormones. The adrenal 
and testicular tissues lose their ability to convert the cholesterol to the pregnenolone; 
therefore, they are destroyed due to accumulation of cholesterol and cholesterol ester (Lin 
et al. 1995; Miller 1997; Miller and Bose 2011). The StAR knockout mouse has the same 
phenotype as human lipoid CAH. Both the level of corticosterone and aldosterone are 
decreased with elevation of ACTH and CRH (corticotropin releasing hormone), 
indicating insufficient production of steroid hormones by the adrenal gland. StAR 
knockout mice prematurely die, as lipid deposits in the adrenal cortex cause disruption 
(Caron et al. 1997).  
Diminished Ovarian Reserve (DOR) is a second most common cause of infertility 
at any age, where the ovaries lose their follicles for unknown reason. A study comparing 
DOR patients during IVF cycles and normal egg donors at a similar age, observed 
multiple differences in gene expression. The StAR and STARD4 genes were significantly 
increased in DOR patient luteinized granulosa cells by microarray analysis compared to 
those of normal patients (Skiadas et al. 2012). 
 Interestingly, there are association between STARD1 expression and non-
alcoholic fatty liver diseases (NAFLD). There is an increase in the expression of 
STARD1 in patients with NAFLD. Simultaneously, hepatic free cholesterol was elevated 
and SREBP2 transcriptional factor with hydroxyl methyl glutaryl-CoA reductase liver 
enzyme were elevated too. Similar results were detected in a mouse model with NAFLD, 
where the accumulation of cholesterol led to development of non-alcoholic steatohepatitis 
(Clark 2012; Caballero et al. 2009; Rooyen et al. 2011). Additional studies investigated 
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mitochondrial cholesterol level in a human hepatocellular carcinoma, the human HepG2 
hematoma cell line, and rat H35 cell line. All samples have shown elevation of 
cholesterol contents of hepatic mitochondria as a mechanism to resist the apoptosis-
inducing agents; additionally, SREBP2 and STARD1 were overexpressed (Montero et al. 
2008; Clark 2012).  
1.11 Aims of this study  
STARD4 and STARD6 have recently been identified in granulosa cells, however, 
only two published studies have examined their expression and possible function in the 
ovary (Skiadas et al. 2012; LaVoie et al. 2014). Our laboratory also has found STARD4 
and STARD6 mRNA and protein in human luteinized granulosa cell preparations by PCR 
and Western blot, respectively. To understand the function of STARD4 and STARD6 in 
the ovary and whether these molecules can contribute to the steroidogenic ability of 
ovarian cells, we need to first have some basic descriptive information regarding these 
proteins in the ovary. My research is mainly focused on localization and expression of 
STARD4 and STARD6 in human ovarian tissue and luteinized granulosa cells.  
Specific Aim 1:    
To determination the presence and expression of STARD4 and STARD6 mRNA and 
proteins in available human ovarian tissues by real-time PCR and Western blot.   
Specific Aim 2:   
To localize STARD4 and STARD6 proteins in different sections of human ovarian 
tissues by using immunohistochemistry.  
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Specific Aim 3:   
To determine the subcellular localization of STARD4 in primary human granulosa cells 
by confocal microscopy.  
Specific Aim 4:  
To determine and clone the major STARD4 mRNA transcript(s) in human luteinized 
granulosa cells.  
Specific Aim 5:    
To compare the size of recombinant human STARD4 protein(s) generated from the 
granulosa cell transcript(s) isolated in Aim 4 with endogenous STARD4 protein from 
human ovarian tissues and granulosa cells by Western blot and to test the steroidogenic 
ability of the resulting recombinant proteins in COS cells expressing the P450scc 
complex. 
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Chapter П 
Materials and Methods 
2.1 Human granulosa cell isolation 
Human follicular fluid including residual granulosa cells was harvested from 
women undergoing reproductive assisted techniques at the Advanced Fertility and 
Reproductive Endocrinology Institute, West Columbia, SC. The follicular fluid was 
transported on ice as soon as possible to the LaVoie lab at the University of South 
Carolina, School of Medicine. All cell isolation and culture procedures were performed in 
a laminar flow hood under sterile conditions. The follicular fluid for each patient was 
kept separate and was transferred into one or more 50 cc tubes, and spun at 2000 rpm in a 
Beckman TJ-6 refrigerated centrifuge for 20 minutes. The supernatant, which was 
comprised of follicular fluid and any contaminating sera, was poured off. Pellets which 
contained blood cells and luteinized granulosa cells, were resuspended in 3 ml of 2X 
enzyme mixture of Hyaluronidase (100 mg/ml, Sigma, St. Louis, Mo) and DNase (6.25 
mg/ml, Sigma), which were dissolved in DMEM/F12 media. The resuspended pellets 
were incubated in the culture incubator for 10 minutes to dissolve granulosa cells 
connections. During the incubation, a discontinuous Percoll (GE Healthcare) gradient 
was prepared for each pellet in a 15 cc tube by adding 4 ml of 70% Percoll in PBS at the 
bottom and overlaying 4 ml of 35% Percoll in DMEM/F12 media with antibiotics on top.  
The cell-enzyme mixture was added gently onto the upper Percoll layer and spun at 2000 
rpm for 30 minutes to partition cells and pellet contaminating blood cells. 
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Individual granulosa cells and granulosa cell clusters formed one to two low density 
bands. Both bands were collected and for each patient’s cells were pooled and placed in 
new tube. The collected sample was brought up to 22-25 ml by adding DMEM/F12 plus 
antibiotics and filtered through 70 µm cell strainer into clean 50 cc tube to remove any 
large granulosa cell clumps. The cells were spun again at 2000 rpm for 20 minutes to 
pellet. After the supernatant was removed, the cell pellet was suspended in 300 to 800 µl 
of DMEM/F12 containing antibiotics and the total volume was measured for the purposes 
of calculating total cell number.  For counting, 10 µl of cell suspension was added to 
1000 µl of DMEM/F12 + ab medium followed by the addition of 100 µl of trypan blue 
dye. The cells were plated in 12 well Falcon plates approximately at 2-4 x 105 live cells 
per well in 1 ml of complete human granulosa cell media (DMEM/F12 + 1X antibiotic 
antimycotic solution, 50 µg/ml gentamicin, and 10% fetal bovine serum (FBS)). Cells 
were cultured at 37 °C with 5% CO2 in humidified cell culture incubator. The media were 
changed daily every 24 hours for 3 days after plating. Some of the plates were treated, 
and some were not treated for confocal staining.  
2.2 Protein isolation 
Whole cell extract (WCE) buffer was used to lyse hGC and COS cells for protein 
isolation. WCE buffer is composed of 50 mM Tris (pH 7.5), 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 150 mM NaCl, 1 mM EDTA, 0.3% 
ALLN, 1% Pierce protease inhibitor cocktail, 1% Pierce phosphatase inhibitor, and sterile 
water. For the COS F2 steroidogenic assay (detailed below) 1 ml of media from each well 
of COS cells was collected and stored at -80 °C for pregnenolone quantification later. 
The rest of the media was aspirated off cells and the hGCs and COS cells were rinsed 
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with 1-2 ml of Dulbecco’s phosphate buffer saline (D-PBS) at room temperature. After 
removing PBS, ice cold WCE buffer was added to each well (100 µl for hGC, 150 µl for 
COS cells). The cells were gently scraped by rubber scraper and transferred to 1.5 ml 
microfuge tube. The cells were incubated with lysis buffer on ice for 30 minutes. The 
mixture lysate was spun at 13,000 rpm in a microcentrifuge (Eppendorf centrifuge 
5417R) for 15 minutes at 4 °C. The supernatant was transferred into new labeled tube, 
and then the volume was measured for the purpose of calculating total protein when 
protein assays were performed later. The tube was stored at -80 °C.   
2.3 Protein quantification 
Quantification of protein was performed by method of Bradford using Bio-Rad 
protein dye reagent and a spectrophotometer set at 595 nm. A standard curve was 
generated using known concentrations of bovine serum albumin protein (BSA, 0-8 
mg/ml), then the protein quantities were extrapolated from the linear region of the 
standard curve. The samples of the protein were diluted (30-50 µg) and aliquoted for 
SDS-PAGE and Western blotting.    
2.4 SDS-polyacrylamide gel electrophoresis and immunoblotting 
The samples with same amount of protein were mixed with 5X bromophenol blue 
loading dye containing 5% 2-mercaptoethanol on ice. Precast 4-20% acrylamide gels 
(Pierce, ThermoScientific) were used with a Bio-Rad minigel apparatus for protein 
separation. Gel running buffer was added (80 ml of 10X running buffer and 720 ml 
nanopure water). The 10X running buffer was made by adding 57.3 g glycine, 12.1 g 
Trizma Base, and 4 g SDS, and filled up to 500 ml with nanopure water. Wells were 
flushed prior to loading. The protein samples were heated at 100 °C for 8 minutes prior to 
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loading, were spun briefly and then entire sample was loaded into the well. The gel was 
run at 200 V for 45 min to 1 h. Protein in gels was transferred to Hybond-P PVDF 
membrane by semi-dry electroblotting (Owl Panther semi-dry electroblotter). Transfer 
buffer was composed of 2.93 g glycine, 5.82 g Trizma Base, and 200 ml methanol, and 
filled up to 1 liter with nanopure water. After wetting the membrane briefly in methanol, 
the transfer stack was prepared layering three sheets of pre-cut, pre-wet (in the transfer 
buffer) Whatman paper, the gel, the PDVF membrane, and three additional sheets of 
Whatman paper. The transfer occurred under environments of constant current, starting at 
a voltage of 9-10 for 90 minutes. 
2.5 Western blot  
The membrane was blocked in 5% nonfat dry milk (Carnation)/1X Tris buffered 
saline with Tween (TTBS) for 1 hour or 2 hour (post-stripping). TTBS (1X) contained 
100 ml 10X TBS, 900 ml nanopure water and 0.5 ml Tween-20 per liter. 10X TBS, pH 
7.5 was composed from 24.2 g Trizma Base, 292 g NaCl, and filled up to 1 liter with 
nanopure water. After blocking, the membrane was washed with 1X TTBS for 3 times, 
10 minutes each. The membrane was placed in a small container to apply primary anti-
body. The antibodies used were against STARD1 (1:1500); this antibody was gift from 
Dr. Steven King and Dr. Douglas Stocco (Texas Tech University, Health Sciences 
Center). STARD4 (1: 200, 0.5 μg/ml, Abgent, Atlanta, GA, Cat. # AP12801a, Lot # 
SA110414AR,), STARD6 (2.5 μg/ml, Abgent, Cat. # AP11832b, Lot # SA 110210AB) 
and CYP11A1 (0.5 μg/ml, Abgent, Cat. # AP7899a, Lot # SH081229L (Atlanta, GA). 
The actin antibody (1:500, Cat. # 4967, Lot # 6) was obtained from Cell Signaling, 
Danvers, MA. The primary antibodies was diluted in 1% nonfat dry milk/1X TTBS, and 
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applied to the membrane, with the exceptions of STARD1 antibody was diluted in 5% 
milk. Approximately 3 ml of antibody solution was used onto each membrane.  
Membranes were incubated with antibodies at 4 °C overnight on a shaker. The secondary 
antibody was pre-absorbed overnight at 4 °C by mixing 2 µl of Goat anti-rabbit 
secondary antibody (Zymed, Cat. # 65-6120, Invitrogen/Life Technologies), 2 μl BSA 
(2µg), and 96 μl PBS. The following day, the membrane was washed with 1X TTBS for 
10 minutes, 3 times. The pre-absorbed secondary antibody was diluted in 5% nonfat dry 
milk/1X TTBS to a final concentration of 1:5000 and applied on the membrane and 
shaken for 1 hour at room temperature. Afterwards, the membrane was washed with 1X 
TTBS 5 times, 10 minutes each. ECL (ThermoScientific) solution was prepared 
immediately before it was used by adding 1:1 of Reagent 1 to Reagent 2 of the ECL kit. 
The ECL solution was added onto well-drained membrane for 1 minute. The membrane 
was drained well, and then the membrane was placed inside a film cassette between two 
pieces of transparency plastic. A spectrum of timed film exposures in the dark room was 
performed and developed (Classic X-ray Film/ Research products International Corp). 
After exposure, the membrane was washed with 1X TTBS for 5 minutes, 3 times each to 
prepare for stripping.  
2.6 Stripping immunoblots 
The stripping buffer (50 ml) was made up of 6.25 ml 0.5 M Tris-Cl (pH 6.8), 10 ml 
10% SDS, 0.35 ml 2-mercaptoethanol, and 33.4 ml nanopure water. The membrane was 
washed 3 times, 5 minutes each with 1X TTBS. The 1X TTBS was poured off and 
approximately 50 ml of erasing buffer was added to each membrane. The membrane was 
placed in a hybridization oven preheated at 60 °C with agitation for 45 minutes. The 
 27 
 
erasing buffer was poured off, and the membrane was washed 4-5 times in 1X TTBS for 
10-15 minutes each over the course of an hour. The membrane was blocked for 2 hours 
before applying another primary antibody. 
2.7 RNA Isolation and cDNA Synthesis 
RNA was isolated from human ovarian tissues. The frozen luteal tissues were 
obtained from the Cooperative Human Tissue Network (University of Alabama) and the 
two follicular phase ovarian biopsy samples were collected by Dr. LaVoie in cooperation 
with the Dept. of Obstetrics and Gynecology. All work with human tissues was reviewed 
and approved by the University of South Carolina Institutional Review Board. The tissue 
biopsies were placed on dry ice until the lysis buffer was added. Trizol (500 µl) was 
added to each sample, then tissue samples were homogenized with 10 strokes of a 
Dounce homogenizer to shear the tissue. The sample was transferred to RNase-free 
microfuge tube and incubated for 5-10 minutes at room temperature. Then, the samples 
were centrifuged for 1 minute at 12,000 xg at 4 °C to pellet non-soluble tissue and only 
the supernatant of each sample was pipetted and transferred into new RNase-free tube. 
An equal volume of 95-100% ethanol was added and mixed thoroughly. Each lysate 
sample was loaded into Zymo-Spin column (Directzol Kit, Zymo Research) and 
centrifuged for 1 minute at 15000 xg in a microfuge at 4 °C. RNA Wash buffer (400 µl) 
was added into each column and centrifuged for 1 minute. DNAse cocktail (80 µl) was 
added to each column and incubated for 15-20 minutes at room temperature then 
centrifuged for 30 seconds. The DNAse cocktail was prepared immediately before it used 
according to kit instructions. RNA Prewash buffer (400 µl) was added into each column 
and centrifuged for 1 minute. After repeating the previous step, 700 µl of RNA Wash 
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buffer was added into each column and centrifuged for 1 minute. The columns were 
centrifuged for 2 minutes more to dry the columns. The flow-through was discarded in all 
previous steps. The RNA was eluted from the column by adding 40 µl of RNase-free 
water, incubating 5 min at room temperature, and collecting the fluid in new collecting 
tubes by centrifuging for 2 minutes. The RNA concentrations were assessed by 
spectrophotometer at wavelength of 260 nm, then diluted for cDNA synthesis. The 
samples were kept on ice for use or stored at - 80°C. 
 The diluted RNA samples were reverse transcribed into cDNA using Bio-Rad 
iScript cDNA synthesis kit. The reaction assembled by adding 15 µl of RNA sample (400 
ng), 4 µl of 5X iScript reaction buffer, and 1 µl of iScript Reverse Transcriptase enzyme. 
The tubes were incubated for 2 minutes at room temperature, then the reaction was 
carried out in a thermal cycler for 5 minutes at 25 °C, 30 minutes at 42 °C, and 5 minutes 
at 85 °C, and held at 4 °C or placed on ice.  Each sample of cDNA was diluted with 
DNase/RNase-free water to concentration of 10 ng/µl. The cDNA either were kept on ice 
to use for a real time PCR or stored at -20 °C.    
2.8 Real-time PCR 
To quantify the amount of STARD4 and STARD6 transcripts in different ovarian 
tissues, real-time PCR was used. The cDNA samples were amplified in duplicate or 
triplicate by using the iCycler Real-Time PCR Detection system (Bio-Rad). A water 
negative control was included in each PCR run. Each PCR reaction was composed of 0.2-
1.0 ng/µl cDNA, 2X SsoAdvanced SYBR Green Supermix (Bio-Rad), upstream primer, 
and the same amount of downstream primer with concentrations of 600 nM for 
hSTARD4, and 300 nM for hSTARD6, and PCR-grade water to bring the volume to 20 
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µl. The PCR upstream primer for hSTARD4 was 5ʹ-CAAAGCCCAAGGTGTTATAGA 
TGAC-3ʹ and the downstream primer was 5ʹ-ACAGCAATTCTCTTCAAAGTTCTCC-
3ʹ. The PCR upstream primer for hSTARD6 was 5ʹ-TTCATATGTCATACCATTACAC 
AAAG-3ʹ and downstream primer was 5ʹ-CTCATTTCTGTCTGGACAAACATCAC-3ʹ. 
The real-time PCR was performed with initial denaturation at 95 °C for 2.5 min followed 
by 40 cycles for hSTARD4 or 45 cycles for hSTARD6 of denaturation for 15 seconds at 
95 °C, annealing for 30 seconds at 62 °C (hSTARD4) or at 60 °C (hSTARD6), 
elongation for 30 seconds at 72 °C. A ten minute final extension at 72 °C was performed. 
A single product was confirmed by the presence of a single melting curve peak and the 
average threshold cycle (Ct value) was used to quantify the results. Human TATA-box 
binding protein (hTBP) was used as an internal amplification control as our lab has found 
this mRNA to be constitutively expressed. The PCR primers for hTBP generated an 87-
bp amplicon and were derived from GenBank. The upstream primer was 5ʹ-CACG 
GCACTGATTTTCAGTTC-3ʹ and the downstream primer was 5ʹ-TCTTGCTGCCAGT 
CTGGACT-3ʹ with concentration of 312.5 nM/ 20 µl reaction. All amplicons derived 
from these primers sets have been previously sequenced to confirm the amplicon identity 
and characterized by others in the laboratory. Target mRNA starting quantity was 
performed by the standard curve method. A standard curve was generated for each 
amplicon by serial diluting a known amount of purified amplicon, determining the Ct 
value for each starting amplicon concentration. Ct values for tissue were extrapolated 
from a linear plot of log concentration and Ct values. The quantity of STARD4 or 
STARD6 in each tissue was normalized to its corresponding quantity of hTBP. 
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2.9 Immunofluorscent labeling of STARD4 for confocal imaging 
The hGC and COS-1 cells were fixed in 2% paraformaldehyde and stored at 4°C 
until use.  Coverslips were placed in a fresh 6-well cell culture plate for staining. The 
cells were incubated with 1 ml of PBS/ 0.01Glycine/ 0.1% Triton-X per well for 15 
minutes, 3 times. The cells were incubated with 5% IgG-free BSA/PBS for 10 minutes. 
One ml of normal donkey serum (5 %), which dissolved in 1% BSA/PBS, was used as 
blocking solution for 10 minutes. Each well of the cells were incubated with 1 ml of 
primary antibody, which was diluted in 1% BSA/PBS, for 1 hour at 37 °C. The primary 
antibodies included STARD4 Abgent rabbit antibody at a concentration 1:100 (Cat # 
AP12801a; Lot # SA110414AR), and Glucose-regulated protein 78 (GRP78) Lot # 
J2214; Santa Cruz goat polyclonal antibody at a concentration 1:20. The coverslips were 
washed with 1.5 ml of 1% BSA/PBS twice for 15 minutes, then incubated with 1 ml of 
5% normal donkey serum per well for 10 minutes. The plates were covered with foil in 
all subsequent steps. The cells were incubated with 1 ml of secondary fluorescent 
antibody per well (diluted in 1 % BSA/PBS) for one hour at 37 °C. The secondary 
antibody included donkey anti-rabbit (DAR-IgG, Cy3) antibody with concentration of 
1:100 (Code # 711-165-152; Lot # 118786) and donkey anti-goat (DAG-IgG, Cy2) 
antibody with concentration of 1:100 (Code # 705-225-003; Lot # 90026). Both 
secondary antibodies obtained from Jackson ImmunoResearch, USA.  The cells were 
washed with 1 ml of 1% BSA/PBS per well for 15 minutes two times, and the third wash 
with 1.5 ml of PBS for 15 minutes. For double-labeling, the cells were incubated with 
STARD4 primary antibody and Cy3 secondary antibody first, then after washing, we 
repeated the procedure for the GRP 78 primary antibody and Cy2 secondary antibody. To 
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visualize the nucleus, the cells were incubated with 1 ml of 5 mg/ml 4’,6-diamidine-2-
phynylindole dihydrochloride  (DAPI) per well for 15 minutes. The plates were washed 
with 1.5 ml of PBS for 15 minutes twice. Most of the incubation and washing steps were 
done on the shaker, except the primary and secondary antibodies incubations. The 
coverslips were mounted with one drop of DABCO in the middle of the slide, and slowly 
pulled down the coverslips on the slide to avoid bubbles.  
2.10 Confocal imaging  
A Zeiss LSM 510 META Confocal Laser Microscope was used to image the 
slides. The excitation/emission wavelengths for DAPI complexes was 358 nm/461 nm. 
The excitation/emission wavelengths for Cy3 complexes was 550 nm/570 nm. The 
excitation/emission wavelengths for Cy2 complexes was 492 nm/510 nm. 
2.11 Immunohistochemistry 
Paraffin-embedded sections of human ovarian tissues with thickness of 5-8 µm 
were placed on poly-lysine coated microscope slides. The sections were deparaffinized 
by xylene and rehydrated by series of ethanol washes, then rinsed with tap water. Antigen 
retrieval procedure was performed to unmask the antigen sites (Gillio et al. 2003). The 
sections were immersed in 0.01 M citrate buffer solution with pH 6.0, then they were 
heated by microwave in microwave pressure cooker for 20 minutes at 800 W followed by 
15 minutes at 300 W. Slides were allowed to cool for 10-15 minutes then rinsed with 
water for 5 minutes followed by washing in D-PBS for 10 minutes. Endogenous 
peroxidase activity was blocked by incubating the slides in the 0.3% peroxide mixed with 
methanol for 40 minutes. Slides were washed by D-PBS for 10 minutes. Sections were 
incubated for an hour in the blocking solution of 10% goat serum-PBS. An initial dilution 
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series of each primary antibodies was tested to determine the optimal concentration for 
IHC. To localize human STARD4 and human STARD6 proteins, the human ovarian 
tissue sections were incubated in 200 µl of STARD4 (1:100, Abgent, Cat # AP12801a; 
Lot # SA110414AR), or STARD6 (1:100, Abgent, Cat. # AP11832b, Lot # SA 
110210AB) primary rabbit antibodies overnight at 4 °C. The negative control slides were 
incubated in blocking solution only. After washing with D-PBS, the tissue sections were 
incubated in 200 µl of goat anti-rabbit (GAR) secondary antibodies with concentration of 
1:600.  
 To visualize bounded antibodies, the slides were incubated with 3,3-
diaminobenzidine (DAB) solution  for exactly 3 minutes at room temperature then 
washed in tap water. Subsequently, the sections were incubated for 15 seconds in 100% 
hematoxylin solution to counterstain the tissues, then washed in tap water for 10 minutes. 
The slides were dehydrated by series of ethanol washes and xylene. Positive staining was 
present as a brown color. The specificity of immunohistochemistry signal was determined 
by performing preabsorption studies with the respective blocking peptides for STARD4 
or STARD6 primary antibodies. Primary antibodies were incubated overnight at 4 °C 
with or without 200-fold molar excess of its target peptide (Abgent) prior to use. The 
sections were examined with 10, 20, 40, and 63x objectives using a Zeiss microscope 
(Carl Zeiss MicroImaging, Inc., Thornwood, NY). Images were captured using a SPOT 
camera and software (Diagnostic Systems Inc., Sterling Heights, MI). Final images were 
generated using Photoshop. 
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2.12 Cloning of human STARD4 transcripts  
Pooled cultured human granulosa cells from multiple patients was used to make 
poly (A) RNA. Human granulosa cells total RNA (91.7 µg) was utilized as starting 
material with the MicroPoly (A) Purist Kit according to the manufacturer’s instructions 
(Ambion). After precipitating the RNA sample, the resuspended RNA pellet was bound 
to Oligo (dT) cellulose. The recovered volume of poly (A) RNA was 10 µl with 
concentration of 126 ng/µl. The hGC cDNA library was made from poly (A) RNA using 
the Clontech Marathon cDNA Amplification Kit (Takara Bio Company, USA) with 
starting amount approximately 0.630 µg of poly (A) RNA. Human placental poly (A) 
RNA (1 µg), provided with the kit, was run at the same time as a positive control.  The 
first and second strands of cDNA were synthesized according to the kit instructions. After 
the second-strand was made, an aliquot of the sample was ligated to Marathon cDNA 
Adaptors. Two dilutions, 1:50 and 1:250, were prepared for the hGC and placental 
adaptor-ligated double-stranded cDNA libraries to perform the nested 5ʹ and 3ʹ RACE-
PCR reactions.  
 The hGC adaptor-ligated cDNA (1:250) mixed with either hSTARD4-nested-3’ 
RACE-US (5ʹ-CATAGCATTGAAGAAGATAAGTGGCGAGTTGC-3ʹ), or hSTARD4-
nested-5’ RACE-DS (5ʹ-ATGGCTGTATCTACCGCAGACTGAGGAATC-3ʹ), and 
Adaptor primer 1 for the first outer reaction of 25 cycles at annealing temperature of 68 
°C, melting temperature of 94 °C, and 72 °C for extension. The PCR products of the first 
reaction was diluted by adding 245 µl of Tricine EDTA buffer to 5 µl from the first 
reaction. For the second nested reaction, the diluted product was added to either 
hSTARD4-3-RACEex4-US (5ʹ-AGGGCCTTGTCGTTTGGATTGGGACAGCTTG) or 
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hSTARD4-5-RACEex4-DS (5ʹ-CAAGCTGTCCCAATCCAAACGACAAGGCCCT), 
and adaptor primer 2 for 20 cycles with annealing temperature at 68 °C. The PCR 
products were cloned into PCRII vector (4.0 kb) by TA cloning, then transformed into 
TOP 10 One Shot competent E. coli cells and plated on LB-agar plates containing 
ampicillin (50 µg/ml) and grown overnight. X-Gal was used to differentiate between the 
colonies with plasmid inserts and those without. The brightest white colonies were 
cultured in liquid Lennox Broth base media (LB Broth, Life Technology) with ampicillin 
overnight at 37 °C in the shaker incubator. Plasmids were purified using the QIAprep 
Spin Miniprep Kit.  Miniprepped plasmids were screened for inserts by EcoRI restriction 
enzyme digest and run on 1.2% agarose gels. The positive plasmid products were sent to 
Genewiz Company for sequencing. The sequence results were analyzed by BLAST, and 
they found to match Homo sapiens StAR-related lipid transfer domain containing 4, 
mRNA, and variants X1, X4, and X5 transcripts at GenBank, NCBI website.  
 The different transcripts were aligned with the predicted wildtype STARD4 
mRNA in order to design primers for full length transcripts. Primers were designed to the 
conserved 5ʹ-UTR and near the stop codon to try to amplify the wildtype and full-length 
variants. The upstream primer was hSTARD4FL-US (5ʹ-CTTCCACGTCCTTGCTTCA 
CCTCAG) and the downstream primer was hSTARD4FL-DS (5ʹ-GCCATGTAGCTGA 
GAGAGTTGATCTG). Full length hSTARD4 transcripts were amplified by PCR using 
hGC Marathon cDNA library without adaptors, hSTARD4FL upstream and downstream 
primers with Advantage 2 polymerase and 10X Advantage 2 PCR buffer for 35 cycles; 
under the condition of 94 °C melting temperature for 15 seconds, Annealing temperature 
at 65 °C for 30 seconds, and extension temperature at 72 °C for 2 minutes. PCR products 
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were gel purified from 1.2 % agarose gels and cloned into the PCR2.1-TOPO vector and 
transformed into TOP 10 One Shot competent E. coli cells. The brightest white colonies 
was cultured in liquid LB Broth media with ampicillin as mentioned above, then the 
plasmids DNA purified by QIAprep Spin Miniprep Kit and screened by EcoRI digest. 
The positive plasmid products were sent to Genewiz Company for sequencing. The 
resulting sequences were matched again to Homo sapiens StAR-related lipid transfer 
domain containing 4, mRNA, and their variants transcripts at GenBank. The clones 
corresponded to the predicted STARD4 wildtype and one variant with an exon 4 deletion.  
The exon 4 deletion introduces a premature stop codon.   
 The positive inserts were excised using EcoRI enzyme from PCR2.1-TOPO 
vector and ligated into linearized pcDNA 3.1, an expression vector. The pcDNA3.1 
vector was linearized by EcoRI enzyme and ends dephosphorylated with calf intestinal 
alkaline phosphatase according to the instructions of the manufacturer (Promega). The 
dephosphorylated pcDNA 3.1 was purified using the QIAquick PCR purification kit. The 
ligation reaction was done using T4 DNA ligase and 1:1, 1:3, or 3:1 molar ratios of 
vector:insert DNA. The reactions were incubated for 3 hours at room temperature and 
transformed into DH5α competent E. coli cells. The overnight liquid cultures were 
purified by QIAprep Spin Miniprep Kit, and screened by EcoRI enzyme and agarose gels 
for the predicted sizes of the STARD4 inserts.  
 The positive pcDNA3.1 with STARD4 inserts were screened for forward and 
reverse orientation by EcoRV enzyme. The forward insert yielded a band of 535 bp, and 
the reverse orientation had a band size of 204 bp. The positive plasmids with forward 
orientation were sent into Genewiz Company for sequence and orientation confirmation. 
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Larger scaled plasmid preps for transfection were purified according to QIAGEN 
Plasmid Midi and Maxi Purification Kit.  
2.13 COS-1 cells culture 
COS-1 cells were resurrected from frozen stock and incubated in a 10 cm culture 
dish with COS-1 complete media (DMEM/F12, 1X antibiotic antimycotic solution, 10% 
FBS) and split every 3-4 days. When the cells were at least 90% confluent, the cells were 
detached by adding 2 ml of Trypsin-EDTA solution and incubated in the incubator for 3-
4 minutes with periodic dish shaking and microscopic inspection. When the cells were 
mostly detached, 4 ml of COS-1 complete media was added, and the whole solution was 
transferred to 50 cc tube. The cells were spun at 1200 rpm for 8 minute at 4 °C. After 
removing the supernatant, the cell pellet was resuspended in fresh COS-1 complete 
media. One 10 cm dish of near confluent cells was used to seed all the wells of a 6-well 
culture plate. Each well received 2 ml of media.  For the COS-F2 assay below, 10 wells 
were plated.    
2.14 COS-F2 steroidogenic assay  
To test the steroidogenic ability of full-length STARD4 and truncated STARD4 
transcripts derived from human granulosa cells, the COS-F2 steroidogenic assay was 
utilized. COS-1 cells were split into 6-well culture dishes and cultured for two days 
before the experiment set-up. Cells were 60-80% confluent at the start of transfection. All 
plasmids were amplified in DH5α bacteria and purified using the Qiagen Midi Prep kit.  
For each well, 2 µg of plasmid DNA was prepared which included 1 µg of pCMV-F2 
plasmid (which makes a fusion protein with all components of the P450scc complex 
needed to make steroids), 10 ng of Renilla Luciferase plasmid (p-tkRL-Luc, a 
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transfection control), and equimolar amounts of pcDNA-hSTARD4 FL-6 (encodes 
wildtype STARD4) or pcDNA-hSTARD4 FL-13 (encodes truncated STARD4) or the 
backbone vector pcDNA3.1 (negative control).  When necessary the pcDNA3.1 vector 
was used to normalize DNA to 2 µg.  In addition, as a positive control to demonstrate the 
F2 plasmid was working, additional wells were transfected with pCMV-STARD1, which 
has consistently been shown to increase pregnenolone production in COS-1 cells in the 
presence of the F2 plasmid. All plasmids were diluted in antibiotic-free, serum-free 
DMEM/F12 and combined with Lipofectamine (8 µl/well, Invitrogen) diluted in similar 
media and incubated for 15-20 min to allow DNA-lipid complex formation. DMEM/F12 
was added up to 1 ml total/well and the transfection mixture was overlaid onto rinsed 
COS-1 cells, which were incubated for 6 h. Cells were transfected in duplicate wells.  
The transfection mix was removed and transfected COS-1 cells received 2 ml of 
complete media. After a recovery period of 18-19 hours, the medium was replaced with 2 
ml of fresh complete medium and incubated an additional 24 hours. At the end of the 24-
hour period, 1 ml of the media was collected from each well and stored for Pregnenolone 
ELISA. One well of each duplicate was lysed with whole cell extract lysis buffer 
(described above) for Western blot.  The second well was lysed with Passive lysis buffer 
(Promega) for luciferase assay.  
2.15 Luciferase Assay 
COS cells were lysed in 1X Passive lysis buffer and stored at -80 °C. The samples 
were thawed and briefly mixed by vortex. The samples were spun down in 
microcentrifuge at 14,000 rpm for 2 minutes and then the supernatant was transferred to 
new labeled tube. Renilla luciferase activity was measured with reagents in the Dual-
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luciferase assay kit. Twenty µl of sample was assayed with 100 µl of Renilla luciferin 
substrate. Light production was measured with a Luminometer (TD-20/20 Turner 
Designs).  
2.16 Pregnenolone ELISA assay 
Pregnenolone secretion into the media by COS-1 cells used in the F2 
steroidogenic assay was measured by ELISA (Alpco).  The samples were thawed and 
spun in the microcentrifuge at 14,000 rpm for 2 minutes to pellet cell debris and clarified 
supernatant was transferred to a clean tube. Wash buffer, biotin conjugate, and 
Horseradish Peroxidase conjugate solutions (HRP) were prepared before starting and kept 
a room temperature. Pregnenolone standards, high and low kit controls, and samples (50 
µl) were pipetted into assay wells in duplicate. Biotin conjugate working solution (100 
µl) was added into each well and the microwell plate was incubated on plate shaker for 
one hour at room temperature. The wells were washed 5 times with 300 µl of diluted 
wash buffer per well and taped firmly against absorbent paper to ensure that all wells are 
empty. After aspiration of the final wash, the plate was incubated on a plate shaker for 30 
minutes with 150 µl of HRP conjugated working solution in each well. The plate was 
washed 5 times by 300 µl of wash buffer per well. 150 µl of TMB substrate was added 
into each well at timed intervals and incubated on the shaker for 10-15 minutes. After 
adding 50 µl of stop solution into each well at timed intervals, the plate was scanned with 
a microwell plate reader (Benchmark plus, Bio-Rad laboratories) at 450 nm to get the 
optical density (OD) reading. Pregnenolone concentrations were extrapolated from a 
standard curve of log concentration and OD values. It was necessary to dilute some  
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samples 1:2, 1:5, or 1:10 before the assay to have their values fall in the reliable region of 
the standard curve. Pregnenolone concentrations were normalized to total protein in the 
well. 
2.17 Data analysis 
We examined STARD4 and STARD6 immunoreactive proteins in different 
human ovarian sections for almost 15 different patients by immunohistochemistry. We 
localized STARD4 and STARD6 protein in almost 43 slides for human ovarian follicles 
at different stages. For corpus luteum, we studied around 23 slides of different human 
ovarian sections, while only 10 slides was examined for corpus albicans. The brown 
signal was considered positive. 
Pregnenolone values from the COS-F2 assay were normalized for the protein 
content in the wells. Pregnenolone experiments were repeated three times with three 
different cell batches.  All raw data was natural log (ln) transformed. Data for 3.1 vector, 
STARD4-WT, and STARD4-trunc were subjected to repeated measure ANOVA 
followed by Tukey’s multiple comparison test. STARD1 a positive control was compare 
to 3.1 vector using Paired test. P value ≤ 0.05 was considered significant. 
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Chapter III 
Results 
3.1 Detection of STARD4 and STARD6 mRNAs and protein in human ovarian 
tissues 
To evaluate the presence and relative abundance of STARD4 and STARD6 
mRNA and protein levels in different human ovarian tissues, quantitative PCR and 
Western blots were performed. The ovarian biopsies contained ovarian cortex containing 
follicular tissue, a new corpus luteum (corpus hemorrhagicum (CH)), a mature corpus 
luteum (CL), or a degenerative corpus luteum (corpus albicans). Most of the corpus 
luteum tissue pieces had some adjacent stromal tissue attached, because we were unable 
to remove it from the frozen specimen without thawing.  As normal human ovarian tissue 
is very hard to obtain, we do not have enough samples to analyze for statistics, and 
therefore present the data of the individual samples that we have available. STARD4 and 
STARD6 mRNA levels were extrapolated from a standard curve and normalized for their 
respective house-keeping gene TBP (Figure 3.1). STARD4 mRNA level is higher than 
STARD6 mRNA in both follicular and luteal tissues with the exception of the single 
degenerative corpus luteum. The level of STARD4 mRNA was highest in three of the 
four functional luteal structures which include CH and CL. The level of STARD6 mRNA 
was detected in all the ovarian tissues samples, but showed no expression trend with 
tissue type, although its level was highest in the degenerative corpus luteum sample. 
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Figure 3.2 represents the relative level of STARD4 and STARD6 proteins in 
human ovarian tissues as assessed by Western. These tissues were from most of the same 
ovarian samples used in Fig. 3.1. The Western blots show a STARD4 protein band in 
follicular phase cortex and luteal ovarian tissues with approximate size of 30 kDa. 
STARD6 with size around 43 kDa was also present in all ovarian tissues examined. 
Because the ovarian tissue samples were not purely follicles or corpus luteum tissue, we 
next examined tissue sections of human ovary using immunohistochemistry to localize 
STARD4 and STARD6 in different ovarian cell types and structures.  
Figure 3.3 to 3.7 represent immunohistochemical microscopic images of human 
ovarian tissue sections containing various follicular and luteal structures including 
primordial follicles, unilaminar preantral follicles, multilaminar preantral follicles, antral 
follicles of different sizes, corpora hemorrhagica, corpora lutea, and corpora albicantia. 
Preliminary studies were performed with ovarian tissue sections and different dilutions of 
antibodies to determine the appropriate dilution of antibody to use in subsequent 
experiments. The signal of STARD4 and STARD6 was visualized as a brown color. 
Incubation of tissue sections with secondary antibody only gave no signal (Figures 3.3; 
3.5; 3.6; 3.7: A, B, C; Figure 3.4. A).  
The rabbit anti-STARD4 polyclonal antibody gave a strong signal with a 
concentration of 1:100. The granulosa and theca follicular cells of antral follicles were 
stained positively as were their oocytes (Figure 3.3 E, F and Figure 3.4 B), indicating the 
presence of immunoreactive STARD4 protein. Conversely, the flat epithelial cells 
surrounded the primordial follicles were not stained even though their oocyte still stained 
(Figure 3.3 D). The corpus luteum (Figure 3.5; 3.6 D, E, F) had a strong immunopositive 
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signal, with the cytoplasm of the luteal cell being stained lighter than the nucleus. Cells 
with the appearance of macrophages, the endothelium of blood vessels, and some red 
blood cells in the Figure 3.7. F were stained in the most sections. The corpus albicans, 
which is the degenerative form of corpus luteum, was not stained; additionally, the atretic 
follicles or degenerative follicles were also not stained (Figure 3.7, D, E).  
For STARD6, granulosa and theca cells of antral and advanced follicles were 
positively stained by rabbit anti-STARD6 polyclonal antibody at a concentration of 1:100 
(Figure 3.3 H, I and Figure 3.4 C). The positive signal was observed in the corpus luteum 
as homogenous distribution in the cytoplasm with dark nuclear staining (Figure 3.5 and 
3.6 G, H, I), while the corpus albicans and atretic follicles were not stained (Figure 3.7, 
G, H). The endothelium cells of blood vessels and some RBCs were positively stained 
too (Figure 3.7, I).  
To determine the specificity of STARD4 and STARD6 antibodies, we performed 
the immunohistochemistry with STARD4 or STARD6 antibodies after preabsorbing 
them with their respective blocking peptides. The ovarian tissue sections, were incubated 
with preabsorbed STARD4 antibody, showed reduced signal intensity in granulosa, theca 
(Figure 3.3, J), and luteal cells, even though the signal was not completely abolished. For 
STARD6, even though the signal was not abolished completely, there was reduced signal 
intensity between the slides treated with preabsorbed STARD6 antibody and the ones 
treated with non-preabsorbed STARD6 antibody (Figure 3.3, K). 
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3.2 Subcellular localization of STARD4 in transfected COS-1 cells by 
immunofluorescence microscopy 
The results in this section are with GRP78 and STARD4 are preliminary and have 
not been completely replicated (the experiment was repeated only two times). COS-1 
cells were transfected with a commercially obtained expression plasmid containing the 
predicted wildtype human STARD4 cDNA linked to a myc-DDK tag to yield a fusion 
protein. The transfected COS-1 cells were utilized to probe for GRP78, an endogenous 
marker for the endoplasmic reticulum, and STARD4 using antibodies and confocal 
florescent microscopy. The immunoreactivity for STARD4 protein in COS-1 cells was 
localized throughout the cytoplasm and nucleus with the STARD4 primary antibody, 
whereas GRP78 antibodies showed a bright green signal in the cytoplasm adjacent to the 
nucleus (Figure 3.8). There was no evidence of co-localization of the two labels which 
would have been observed by a yellow signal upon merging the two images. Because of 
this negative result and the difficulty we experienced in optimizing antibodies for use in 
the primary ovarian cells, this part of the project was stopped.  
3.3 Human luteinized granulosa cells express multiple STARD4 mRNA transcripts  
We cloned STARD4 transcripts from human luteinized granulosa cells in order to 
be able to express their proteins and determine their molecular mass. A cDNA library 
was constructed from poly (A) RNA, which was purified from pooled total RNA isolated 
from pooled cultured hGCs. After multiple trials of RACE-PCR, we amplified various 
products by 5ʹ and 3ʹ RACE-nested-PCR for hSTARD4. We used 5ʹ RACE-nested-PCR 
product sequences and NCBI reference sequence entry XM_005271881.1 to design the 
upstream primer to amplify the full-length product. One product of 3ʹ RACE-nested-PCR 
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was used with NCBI reference sequence entry XM_005271884.1 to design the 
downstream primer to isolate full-length STARD4 transcripts. The sequences of 5ʹ and 3ʹ 
RACE products are not shown.   
We found a variation in the exon 1 sequence of two transcripts, but this was in 
non-coding exon 1, which would not affect the translated protein. Figure 3.9 (A) 
represents a diagram of the two major mRNA transcripts from human STARD4 isolated 
from hGCs, and Figure 3.9 (B) represents their cDNA sizes as visualized by agarose gel. 
The first STARD4 transcript possesses all six exons of human STARD4 mRNA 
according to NCBI reverence sequence entry NM_139164.1. The first transcript of 
STARD4 has length of 715 base pairs and predicted to yield full-length STARD4 protein; 
therefore we called the first transcript the full-length or wild-type transcript (STARD4-
WT). The second transcript possesses an exon 4 deletion, which introduces a premature 
stop codon and is predicted to yield one or more truncated proteins. The exon 4 deletion 
transcript has length of 588 base pairs and Figure 3.10 shows the alignment and the 
matching of STARD4-WT and exon 4 deletion transcripts to the human STARD4 mRNA 
obtained from Genbank.   
3.4 Determining the size of recombinant proteins produced from human full-length 
STARD4 and exon four-deleted STARD4 mRNA isolated from hGC  
Transfected COS-1 cells were utilized to evaluate the expression of STARD4 
recombinant proteins and their sizes generated from the cloned cDNA derived from 
human luteinized granulosa cells mRNA transcripts. Figure 3.11 shows the predicted size 
of recombinant STARD4 proteins and their sequences. The full-length protein, which 
was produced from the full-length STARD4 transcript, and the putative truncated 
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proteins produced from the exon 4 deleted STARD4 transcript. The expected size for a 
full-length protein is 205 amino acids, which matches the wild type STARD4 protein 
reported in Genbank, with a predicted molecular weight of 23.52 kDa. The truncated 
STARD4 protein was predicted to produce two possible different sized proteins based on 
analysis of reading frames, with one having 55 amino acids with a predicted molecular 
weight of 6.37 kDa, because the exon 4 deletion transcript introduced premature stop 
codon. The reading frame two produces a protein with 107 amino acids having a 
predicted size of 12.16 kDa. Our STARD4 antibody recognizes the N-terminus so would 
likely not detect the longer truncated protein if translated.  
To confirm protein expression, whole cell extracts were isolated from the 
transfected COS-1 cells. The transfected P450scc complex fusion protein was detected in 
the cells which meant all the plasmids were successfully transfected and expressed. The 
analysis of protein, immunoblot on Figure 3.12 showed only the wild-type STARD4, 
where the band size approximately 24 kDa for the COS-1 cells transfected with full-
length STARD4 plasmid. Conversely, the two predicted sizes of truncated protein did not 
show on the gel even after long exposure. This negative result may mean that the protein 
was made and quickly degraded, the intensity of exposure was not enough, or the protein 
was not made. It is likely that the antibody, which targets the N-terminus, would not 
detect the trunc-1 product. For that, we need to perform more experiments to detect the  
truncated STARD4 protein.     
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3.5 Human full-length STARD4 recombinant protein is able to facilitate de novo 
steroidogenesis in the COS-1 F2 assay   
The COS-1 F2 assay was used to evaluate the steroidogenic ability of the 
recombinant STARD4 full-length and exon 4 deleted transcript proteins. STARD4 
expression vectors transfected with the F2 plasmid and the pregnenolone (P5) levels were 
measured in the media by ELISA. STARD1 has been shown to increase pregnenolone 
production in F2-transfected COS-1 cells, which served as a positive control. The 
experiment was replicated three times. Pregnenolone levels were normalized to the 
concentration of proteins in the well (ng P5/ng protein).  
 Figure 3.13 represents the pregnenolone levels for transfected COS-1 cells 
cultures. COS-1 cells transfected with P450scc and the empty expression vector only 
(pcDNA3.1) showed very low concentration of pregnenolone. The pregnenolone 
production was significantly increased (P < 0.001) in the STARD1 transfected cells with 
a mean increase of 9.8-fold compared to the empty vector control. In the full-length 
STARD4 transfected cells, the increase in pregnenolone was statistically significant (P < 
0.05) at a mean 3.8-fold compared to the empty control vector indicating that the full-
length STARD4 protein is able to facilitate cholesterol entry into the mitochondria to 
promote steroidogenesis. Even though the pregnenolone level produced by STARD4-
truncated protein was increased by 2.1-fold, it was not statistically significant (P > 0.05) 
compared to the empty vector only.  
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Figure 3.1. STARD4 and STARD6 mRNA expression in human ovarian tissues. The 
RNA was isolated from ovarian tissues at various stages (follicular and luteal phases), 
and mRNA levels was measured by real-time PCR. CL (Corpus luteum); CH (Corpus 
hemorrhagicum). (*/ **) indicate that the tissue samples with same asterisks were taken 
from the same ovary. STARD4 and STARD6 mRNA levels was normalized to TATA 
box-binding protein (TBP, an unregulated house-keeping gene).  
 
 
 
 
 
 
 
 48 
 
 
Figure 3.2. Western blot analyses of STARD4 and STARD6 proteins in human 
ovarian tissue samples. The blots show the expression of STARD4 and STARD6 
proteins in all ovarian tissue sections.  The proteins samples represent whole cell extracts 
from ovarian tissue sections indicated. The whole proteins were separated by SDS-
polyacrylamide gel electrophoresis using 4-20% gradient gels and transferred to PVDF 
membrane and probed with antibodies for the indicated proteins. The right membrane has 
50 µg of proteins, while the amount of the same proteins in the left membrane is 30 µg. 
The tissue sections contained mix of stromal and follicular tissues; or stromal and luteal 
tissues. Ovarian cortex tissue (contained small and medium antral follicles); CL (Corpus 
luteum); CH (Corpus hemorrhagicum).  
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Figure 3.3. Immunolocalization of STARD4 and STARD6 in human ovarian tissue 
sections. A, D, G represent biopsies of ovarian cortex showing primordial and small 
preantral follicles and stromal tissue. B, E, H represent small antral follicles. C, F, I, K, J 
represent medium antral follicles. A-C negative control sections probed with secondary 
antibody only. D-F sections probed with STARD4 primary antibody. G-I probed with 
STARD6 primary antibody. J and K are a control; where (J) was probed with STARD4 
blocking peptide, and (K) probed with STARD6 blocking peptide. The positive staining 
is shown in brown. All sections were counterstained with hematoxylin. The 
magnification for all sections is 20X with scale bar of 65 µm. A= Antrum, G= granulosa 
cells, T= theca cells, St= stromal tissue. The small square regions in the right side 
column are enlarged on the next figure.  
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Figure 3.4. Immunolocalization of STARD4 and STARD6 proteins in human antral 
follicles. The pictures represent 63X magnification of the small square on the previous 
figure. Image A represents a negative control which is probed with secondary antibody 
only. The section B is probed with STARD4 antibody. The section C is probed with 
STARD6 antibody. A= antrum, G= granulosa cells, T= theca cells, St= stromal tissue. 
The positive staining is shown in brown. All sections were counterstained with 
hematoxylin. The scale bar is 20 µm.  The light settings were the same for all images in 
this figure. 
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Figure 3.5. Immunolocalization of STARD4 and STARD6 in the corpus luteum of 
human ovarian tissues. A-C negative control sections probed with secondary antibody 
only. D-F sections probed with STARD4 primary antibody. G-I sections are probed with 
STARD6 primary antibody. The positive staining is shown in brown. All sections were 
counterstained with hematoxylin. The magnification is 20X with scale bar of 65 µm. 
LC= luteal cells, St= stromal tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52 
 
 
 
Figure 3.6. Immunolocalization of STARD4 and STARD6 in the corpus luteum of 
human ovarian tissues. A-C negative control sections probed with secondary antibody 
only. D-F sections probed with STARD4 primary antibody. G-I sections are probed with 
STARD6 primary antibody. The positive staining is shown in brown. All sections were 
counterstained with hematoxylin. The magnification for (A, B, D, E, G, H) is 40X with 
scale bar of 25 µm; while for (C, F, I) is 63X with scale bar of 16 µm, LC= luteal cells, 
St= stromal tissue.  
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Figure 3.7. Immunolocalization of STARD4 and STARD6 in human ovarian tissue 
sections. A, D, G represent biopsies obtained from ovarian cortex of corpus albicans. B, 
E, H represent atretic follicles. C, F, I represent blood vessels in ovarian stroma with 20X 
magnification and scale bar of 65 µm. The magnification of A, B, D, E, G, H sections is 
10X with scale bar of 100 µm. A-C negative control sections probed with secondary 
antibody only. D-F sections probed with STARD4 primary antibody. G-I sections probed 
with STARD6 primary antibody. The positive staining is shown in brown. All sections 
were counterstained with hematoxylin.  
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Figure 3.8. Immunofluorescence confocal microscopy assessment of recombinant 
STARD4 and endogenous GRP78 proteins in transfected COS-1 cells. COS-1 cells 
were transfected with myc-DKK-tagged STARD4 expression plasmid then prepared for 
double labeling immunofluorescence confocal microscopy. A-C each represents 40X 
magnification of the same visual field under the microscope. DAPI is shown as blue color 
staining the nucleus. STARD4 primary antibody was detected as the red color of CY3 
donkey anti-rabbit secondary antibody. GRP78 primary antibody detected by CY2 
donkey anti-goat secondary antibody is shown in green. Scale bar is 20 µm.       
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(A) 
 
(B) 
 
 
Figure 3.9. Schematic view of the major mRNA transcripts of human STARD4 
which were isolated from human granulosa cells and their sizes on agarose gel. (A) 
The predicted exons of the STARD4 transcripts are shown according to GenBank NCBI 
Reference Sequence entry NM_139164.1. The STARD4 wild-type (WT) possess all six 
exons of human STARD4 mRNA illustrated here with boxes and codes for a 205 amino 
acids protein. The STARD4-trunc transcript is lacking exon 4 and is predicted to produce 
a 55 or 107 amino acid protein.  
(B) An agarose gel showing different STARD4 cDNA sizes. The cloned cDNAs were 
digested from the PCR2.1 cloning vector with EcoRI and separated using 1.2% agarose 
gel. The gel purified cDNA inserts were subsequently inserted into the pcDNA3.1 
plasmid for expression purposes. 
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STARD4 mRNA     CTTCCACGTCCTTGCTTCACCTCAGGTAAAGAGAGAAGTAATGGAAGGCCTGTCTGATGT 
STARD4-trunc    CTTCCACGTCCTTGCTTCACCTCAGGTAAAGAGAGAAGTAATGGAAGGCCTGTCTGATGT 
STARD4-WT       CTTCCACGTCCTTGCTTCACCTCAGGTAAAGAGAGAAGTAATGGAAGGCCTGTCTGATGT 
                ************************************************************ 
 
STARD4 mRNA     TGCTTCTTTTGCAACTAAACTTAAAAACACTCTCATCCAGTACCATAGCATTGAAGAAGA 
STARD4-trunc    TGCTTCTTTTGCAACTAAACTTAAAAACACTCTCATCCAGTACCATAGCATTGAAGAAGA 
STARD4-WT       TGCTTCTTTTGCAACTAAACTTAAAAACACTCTCATCCAGTACCATAGCATTGAAGAAGA 
                ************************************************************ 
 
STARD4 mRNA     TAAGTGGCGAGTTGCTAAGAAAACGAAAGATGTAACTGTTTGGAGAAAACCCTCAGAAGA 
STARD4-trunc    TAAGTGGCGAGTTGCTAAGAAAACGAAAGATGTAACTGTTTGGAGAAAACCCTCAGAAGA 
STARD4-WT       TAAGTGGCGAGTTGCTAAGAAAACGAAAGATGTAACTGTTTGGAGAAAACCCTCAGAAGA 
                ************************************************************ 
 
STARD4 mRNA     ATTTAATGGATATCTCTACAAAGCCCAAGGTGTTATAGATGACCTTGTCTATAGTATAAT 
STARD4-trunc    ATTTAATGGATATCT--------------------------------------------- 
STARD4-WT       ATTTAATGGATATCTCTACAAAGCCCAAGGTGTTATAGATGACCTTGTCTATAGTATAAT 
                *************** 
                                              
STARD4 mRNA     AGACCATATACGCCCAGGGCCTTGTCGTTTGGATTGGGACAGCTTGATGACTTCTTTGGA 
STARD4-trunc    ------------------------------------------------------------ 
STARD4-WT       AGACCATATACGCCCAGGGCCTTGTCGTTTGGATTGGGACAGCTTGATGACTTCTTTGGA 
                                                                                     
STARD4 mRNA     TATTCTGGAGAACTTTGAAGAGAATTGCTGTGTGATGCGTTACACTACTGCTGGTCAGCT 
STARD4-trun     ----------------------AATTGCTGTGTGATGCGTTACACTACTGCTGGTCAGCT 
STARD4-WT       TATTCTGGAGAACTTTGAAGAGAATTGCTGTGTGATGCGTTACACTACTGCTGGTCAGCT 
                                      ************************************** 
 
STARD4 mRNA     TTGGAATATAATTTCCCCAAGAGAATTTGTTGATTTCTCCTATACTGTGGGCTATAAAGA 
STARD4-trunc    TTGGAATATAATTTCCCCAAGAGAATTTGTTGATTTCTCCTATACTGTGGGCTATAAAGA 
STARD4-WT       TTGGAATATAATTTCCCCAAGAGAATTTGTTGATTTCTCCTATACTGTGGGCTATAAAGA 
                ************************************************************ 
 
STARD4 mRNA     AGGGCTTTTATCTTGTGGAATAAGTCTTGACTGGGATGAAAAGAGACCAGAATTTGTTCG 
STARD4-trunc    AGGGCTTTTATCTTGTGGAATAAGTCTTGACTGGGATGAAAAGAGACCAGAATTTGTTCG 
STARD4-WT       AGGGCTTTTATCTTGTGGAATAAGTCTTGACTGGGATGAAAAGAGACCAGAATTTGTTCG 
                ************************************************************ 
 
STARD4 mRNA     AGGATATAACCATCCCTGTGGTTGGTTTTGTGTTCCACTTAAAGACAACCCAAACCAGAG 
STARD4-trunc    AGGATATAACCATCCCTGTGGTTGGTTTTGTGTTCCACTTAAAGACAACCCAAACCAGAG 
STARD4-WT       AGGATATAACCATCCCTGTGGTTGGTTTTGTGTTCCACTTAAAGACAACCCAAACCAGAG 
                ************************************************************ 
 
STARD4 mRNA     TCTTTTGACAGGATATATTCAGACAGATCTGCGTGGGATGATTCCTCAGTCTGCGGTAGA 
STARD4-trunc    TCTTTTGACAGGATATATTCAGACAGATCTGCGTGGGATGATTCCTCAGTCTGCGGTAGA 
STARD4-WT       TCTTTTGACAGGATATATTCAGACAGATCTGCGTGGGATGATTCCTCAGTCTGCGGTAGA 
                ************************************************************ 
 
STARD4 mRNA     TACAGCCATGGCAAGCACTTTAACCAACTTCTATGGTGATTTACGAAAAGCTTTATGAGA 
STARD4-trunc    TACAGCCATGGCAAGCACTTTAACCAACTTCTATGGTGATTTACGAAAAGCTTTATGAGA 
STARD4-WT       TACAGCCATGGCAAGCACTTTAACCAACTTCTATGGTGATTTACGAAAAGCTTTATGAGA 
                ************************************************************ 
 
STARD4 mRNA     GGCAAAATACATTCAAACTTGTAGTACTACAGATCAACTCTCTCAGCTACATGGCCTGTA 
STARD4-trunc    GGCAAAATACATTCAAACTTGTAGTACTACAGATCAACTCTCTCAGCTACATGGC----- 
STARD4-WT       GGCAAAATACATTCAAACTTGTAGTACTACAGATCAACTCTCTCAGCTACATGGC----- 
                *******************************************************      
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Figure 3.10. The homology and the aligment of STARD4-WT and STARD4 cDNAs. 
The homology of STARD4-WT and STARD4 cDNAfrom GenBank NCBI Reference 
Sequence entry ref|NM_139164.1|. The STARD4-WT transcript is 715 base pair in 
length. ATG = starting codon, TGA = stop codon. Alignment of STARD4 wild-type 
(WT) and truncated (STARD4-trunc) transcripts to STARD4 mRNA using Multiple 
Sequence Alignment by CLUSTALW. (****) indicate complete matching (100%), while 
(-----) indicates the exon 4 deletion in STARD4-truncated transcript.  
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(A) 
 
(B) 
HS-STARD4       MEGLSDVASFATKLKNTLIQYHSIEEDKWRVAKKTKDVTVWRKPSEEFNGYLYKAQGVID 
STARD4-WT       MEGLSDVASFATKLKNTLIQYHSIEEDKWRVAKKTKDVTVWRKPSEEFNGYLYKAQGVID 
STARD4-trunc1   ------------------------------------------------------------ 
STARD4-trunc2   MEGLSDVASFATKLKNTLIQYHSIEEDKWRVAKKTKDVTVWRKPSEEFNGYLIAV----- 
                                                                             
 
HS-STARD4       DLVYSIIDHIRPGPCRLDWDSLMTSLDILENFEENCCVMRYTTAGQLWNIISPREFVDFS 
STARD4-WT       DLVYSIIDHIRPGPCRLDWDSLMTSLDILENFEENCCVMRYTTAGQLWNIISPREFVDFS 
STARD4-trunc1   --------------------------------------MRYTTAGQLWNIISPREFVDFS 
STARD4-trunc2   ------------------------------------------------------------ 
                                                                             
 
HS-STARD4       YTVGYKEGLLSCGISLDWDEKRPEFVRGYNHPCGWFCVPLKDNPNQSLLTGYIQTDLRGM 
STARD4-WT       YTVGYKEGLLSCGISLDWDEKRPEFVRGYNHPCGWFCVPLKDNPNQSLLTGYIQTDLRGM 
STARD4-trunc1   YTVGYKEGLLSCGISLDWDEKRPEFVRGYNHPCGWFCVPLKDNPNQSLLTGYIQTDLRGM 
STARD4-trunc2   ------------------------------------------------------------ 
                                                                             
 
HS-STARD4       IPQSAVDTAMASTLTNFYGDLRKAL 
STARD4-WT       IPQSAVDTAMASTLTNFYGDLRKAL 
STARD4-trunc1   IPQSAVDTAMASTLTNFYGDLRKAL 
STARD4-trunc2   ------------------------- 
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Figure 3.11. Diagram illustrating the predicted sizes of STARD4 wild-type and 
truncated proteins and their alignment with Homo sapiens STARD4 protein. (A) 
Using the Sequence Manipulation Suite and BLAST to predict the sizes of the proteins. 
STARD4-WT yields a protein of 205 amino acids (aa) with molecular weight of 23.52 
kDa. STARD4-truncated transcript is predicated to produce two short proteins, because 
of a premature stope codon and according to different reading frames. STARD4-trunc-1 
matches 107 aa of human STARD4 protein with predicted molecular weight of 12.16 
kDa. STARD4-trunc-2 consists of 55 aa with molecular weight of 6.37 kDa.  
(B) The alignment of STARD4-WT, and both isolated STARD4-truncated protein 
sequences with Homo sapiens STARD4 protein using Multiple Sequence Alignment by 
CLUSTALW. (HS-STARD4) is a Homo sapiens STARD4 protein sequence. The 
sequence of STARD4-WT completely matches the Homo sapiens STARD4.  STARD4-
trunc-1 matches the last 107 amino acids, while the STARD4-trunc-2 matches the first 55 
amino acids of Homo sapiens STARD4 isoform CRA_e with reference ID 
gb|EAW49030.1|.   
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Figure 3.12. Western blot for comparing human recombinant STARD4 and 
endogenous STARD4 proteins. The left panel is transfected COS-1 cells, and the right 
panel is human ovarian tissues and human luteinized granulosa cells (hGC). Both panels 
are from the same blot. All samples were loaded with 25 µg protein, and probed with 
STARD4, STARD1, and CYP11A1 rabbit primary antibodies. Actin reflects protein 
loading. (CL) Corpus luteum.  
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Figure 3.13. COS-F2 steroidogenic assay to assess the pregnenolone production by 
recombinant STARD4 proteins derived from human granulosa cells transcripts. 
COS-1 cells were transfected with equimolar amounts of plasmids encoding recombinant 
STARD4 (wildtype or trunc), STARD1 proteins, or vector only along with the F2 
plasmid which encodes the p450 cholesterol side chain cleavage enzyme complex as a 
fusion protein. Pregnenolone was measured in the media by P5 ELISA from three 
separate transfection experiments. Comparison of STARD4 conditions with 3.1 control 
(empty expression vector) were performed. Asterisk indicates mean is significantly 
different from 3.1 control by ANOVA and Tukey’s Multiple Comparison test, P<0.05. # 
indicates treatment is significantly different from 3.1 control by paired t-test, P<0.001.  
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Chapter IV 
Discussion  
In this study, STARD4 and STARD6 proteins were localized in human ovarian 
steroidogenic cells (granulosa cells, thecal cells, and luteal cells). Only two published 
studies have investigated STARD4 and STARD6 expression in the ovary.  Our results are 
consistent with that of Skiadas et al (2012) that found STARD4 mRNA in human 
granulosa cells isolated from women undergoing assisted reproduction. In addition, a 
previous study by our lab detected STARD6 in porcine ovarian granulosa cells, which is 
similar to our finding in the human ovary (LaVoie et al. 2014). In the pig studies, 
STARD6 mRNA had much higher expression in all ovarian tissues than in the human, as 
determined from standard curves. In pig, STARD6 mRNA and protein levels in mid-
luteal phase or functional corpus luteum were significantly higher than follicles and 
granulosa cells; this was not the case in human ovarian tissues where STARD6 mRNA 
was similar between ovarian tissue with follicles and different stages of functional corpus 
luteum. Our current data with STARD4 mRNA in human ovarian tissues more closely 
approximates what has been reported for pig STARD6 mRNA. Despite our higher levels 
of STARD4 mRNA in the majority of human functional corpora lutea assessed, there was 
no trend in STARD4 protein levels.   
Like STARD1, which is a known major regulator of steroidogenesis, STARD4 
and STARD6 can bind and transport cholesterol. Until recently, STARD4 and STARD6 
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were largely ignored as potential participants in steroidogenesis because they were not 
detected in the ovary, such as with STARD6, or the tissue distribution had not been 
characterized, such as with STARD4 (LaVoie et al. 2014; Soccio et al. 2005). The 
presence of these proteins in ovarian steroidogenic cells gives some suggestion that they 
could have a role in steroidogenesis. Other studies have found STARD4 in the cytoplasm 
of human THP-1 macrophages and Kupffer cells with a co-localization to ER areas 
enriched in acyl-coA cholesterol transferase-1.  
STARD4 is highly regulated by sterol levels indicating that STARD4 has a role in 
maintaining intracellular cholesterol homeostasis (Rodriguez-Agudo et al. 2011). 
Structural studies for STARD6 have shown that STARD6 has folding and hydrophobic 
sterol-binding pocket similar to STARD1; interestingly, STARD6 also interacts with 
mitochondrial membranes (Bose et al. 2008). All together these findings suggest that 
STARD4 and STARD6 may have a role in providing cholesterol substrate to the 
mitochondria.  
In order to determine the size of STARD4 protein from the mRNA of hLGC, we 
attempted to clone all the major transcripts of STARD4 using a combination of 5’ and 3’ 
RACE and traditional high fidelity PCR. We succeeded in isolating two major transcripts 
for STARD4 from pooled cultured human luteinized granulosa cell poly (A) mRNA. The 
longer full-length transcript possesses all six exons of STARD4 with length of 715 base 
pairs and is predicted to produce a full-length STARD4 protein of 205 amino acids with 
normal function. The full-length STARD4 transcript matches a previous cloned human 
transcript at the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/) under the reference sequence entry NM_139164.1. While 
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the second shorter transcript possesses an exon 4 deletion that is predicted to yield 55 
and/or 107 amino acid proteins. The second transcript has been found in fetal brain, bone 
marrow, and pulmonary endothelial artery (NCBI). 
After we transfected the COS-1 cells with our two STARD4 transcripts, we were 
able to generate the full-length recombinant STARD4 protein from the longer cDNA. In 
our studies, the endogenous ovarian STARD4 yields a single band of an approximately 
molecular mass of 30 kDa.  Based on amino acid sequence only, the predicted mass for 
the wild-type STARD4 protein should be 23.5 kDa. The full-length recombinant 
STARD4 protein has size of 24 kDa in COS cell lysates. Similar to our findings, human 
recombinant STARD4 protein expressed in BL21 E. coli cells had a size range between 
22-27 kDa (Rodriguez-Agudo et al. 2008). The major protein band was found at 27 kDa 
with the Histidine tag. However, when the His tag was cleaved by enterokinase, the 
recombinant STARD4 protein run at around 22 kDa (Rodriguez-Agudo et al. 2008). Our 
data in human ovarian tissue and cultured granulosa cells identify a single protein band 
with an apparent molecular mass of approximately 30 kDa. This finding is similar to that 
of human placenta, where STARD4 protein also migrates at an apparent mass of 30 kDa 
(http://www.avivasysbio.com/stard4-antibody-n-terminal-region-oaab09082.html).  
It is possible that posttranslational modifications (PTMs) alter the mass of the 
STARD4 protein made in granulosa cells. It may be that the endogenous STARD4 has 
phosphate groups as posttranslational modifications, which would increase the size of the 
protein by 80 Da for each added phosphate group (Seo and Lee 2003). Other PTMs 
which may occur and change the protein mass significantly are ubiquitination, which 
adds 8.5 kDa for each ubiquitin and acetylation which adds 42 Da for each acetyl group 
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added to a protein (Seo and Lee 2003). The PTM may occur ovarian cells but not in 
transfected COS cell thereby explaining why the recombinant STARD4 protein is smaller 
in size than the endogenous protein. To analyze the PTMs that change the size of our 
protein, we will have to use different techniques; for example, 2-D gel electrophoresis 
and/or mass spectrometry.    
Whereas the full-length protein was detected in transfected COS cell lysates by 
Western blot, the truncated protein was not detected.  Possible explanations for the lack 
of detection of the truncated protein are that the size of the predicted protein is very small 
and may not have resolved well on the Tris-HCl gels, the mRNA for or the truncated 
protein is degraded rapidly, or the protein may not be translated. To resolve these 
questions, we may need to run the protein lysates on Tris-Tricine gels for better 
resolution of small proteins, add proteasome inhibitor to the culture to inhibit protein 
degradation, or do PCR to insure that the mRNA of truncated STARD4 protein is 
transcribed. Another student in our laboratory has in vitro transcribed and translated the 
STARD4 plasmid constructs using a Wheat germ system and resolved the proteins on 
16% Tris-Tricine-SDS-PAGE gels (Yahya and LaVoie, unpublished data).  For the full-
length STARD4 construct a protein of 22 kDa was observed.  For the STARD4 construct 
lacking exon 4 protein two bands of approximately 3 kDa and 6 kDa were observed by 
Western blot using an N-terminal recognizing antibody. Further investigation is required 
know if these two bands are functionally active.  Also should a C-terminal recognizing 
antibody become available in the future we can reprobe our blots. 
We hypothesized that the full-length STARD4 transcript would produce a protein 
in COS-1 cells containing transfected components of the P450scc complex and that 
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STARD4 protein would increase pregnenolone production, and that the truncated protein 
would not be able to increase pregnenolone production. The full-length recombinant 
STARD4 protein shows steroidogenic ability in transfected COS-1 cells, which the 
pregnenolone production is increased by 3.8 fold. Our findings agree with a similar study 
in which transfected COS cells containing wild-type STARD4 and the genes for encoding 
the machinery to convert cholesterol to progesterone, increased progesterone production 
(Soccio et al. 2005). STARD4 protein also had a similar ability to transport cholesterol as 
STARD1 but not to the same amplitude (Soccio et al. 2005). These previous studies and 
our results indicate that STARD4 can somehow transport cholesterol into the 
mitochondria for de novo steroidogenesis. The truncated recombinant STARD4 protein 
did show a small degree of pregnenolone production, which is increased by 2.1-fold 
when compared to the empty vector. This increase was not statistically significant. In 
wild-type or full-length human STARD4 mRNA, exon one is noncoding, while the rest 
of the exons code the entire START domain (Soccio et al. 2002). Deletion of exon 4 in 
truncated STARD4 transcript would result in a truncated protein lacking the bulk of the 
START domain and likely be minimally active or functionally inactive, lacking the 
ability to transfer cholesterol. 
There was no evidence of subcellular co-localization of STARD4 protein in 
transfected COS cells and ER marker, the GRP78 protein, using immunofluorescence 
microscopy; which infers that STARD4 protein is not localized to ER region where the 
GRP78 protein is located. We may need to try another ER marker such as calnexin, 
which is an integral protein of the endoplasmic reticulum and has a function as a 
chaperone. In a previous study, calnexin was co-localized with STARD4 in the cytoplasm 
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and ER of  3T3-L1 cells (Rodriguez-Agudo et al. 2011). We could also test co-
localization with mitochondrial marker like VDAC2 or other vesicular markers. 
Despite the ability of STARD4 and STARD6 to transfer cholesterol, StAR protein 
is still the most important protein to transfer the cholesterol from OMM into IMM for de 
novo steroidogenesis in adrenal gland and gonads.  This is supported by the fact that loss 
of StAR is associated with CAH, a lethal condition if supplemental steroids are not given. 
However, some untreated patients with CAH initially have low levels of adrenal steroids 
which disappear with time (Miller 1997). This initial steroidogenesis could be due in part 
to partial activity of mutant StAR proteins in CAH.  However, this finding of initial low 
steroid secretion in CAH supports the concept of StAR-independent pathways that can 
substitute for StAR deficiency. Thus STARD4 or STARD6 proteins could potentially 
provide low levels of StAR-independent cholesterol transfer into the mitochondria, but 
are not able to fully substitute for the level of StAR activity, because if they could then 
untreated CAH would not be lethal. In addition, the brain and placenta exhibit StAR-
independent steroidogenesis (Miller 1997; Bose et al. 1996; Mellon 1994). 
In summary, STARD4 and STARD6 proteins can transfer cholesterol 
intracellularly. Their function may also extend to transferring cholesterol into the 
mitochondria in steroidogenic cells for the purposes of enhancing de novo 
steroidogenesis (LaVoie et al. 2014; Soccio et al. 2005). The presence of STARD4 and 
STARD6 in ovarian steroidogenic cells lends support to the idea that these molecules 
could participate in steroidogenesis.  Future studies could knockdown these molecules to 
determine their ability to contribute to endogenous steroidogenesis in ovarian or other 
steroidogenic cell types. Future subcellular fractionation studies including isolation of 
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mitochondria, mitochondrial associated membranes, endoplasmic reticulum, and plasma 
membrane fractions could provide further evidence for a role in steroid synthesis or other 
cholesterol-requiring cellular events.  
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